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Abstract 
Macrophage lipoprotein lipase (LPL) contributes to atherogenesis. However, the complete 
effect of LPL hydrolysis products and its free fatty acid (FFA) component on modifying genes 
associated with macrophage-derived foam cell formation are not fully understood. I hypothesized 
that the FFA liberated from lipoproteins by LPL affects the gene expression in macrophages to 
potentially promote atherogenesis. Human microarray analyses on the RNA isolated from THP-1 
macrophages treated with lipoprotein hydrolysis products generated by LPL revealed that selected 
genes associated with ribosome biogenesis, cell cycling, stress response, type I interferon 
signaling, and lipid accumulation were affected (at false discovery rate ≤ 0.03, n=3). Testing the 
effects of either the total FFA component of the hydrolysis products, or individual classes of the 
FFA component, revealed mixed effects on the gene expression profiles. Overall, LPL hydrolysis 
products appear to affect gene expression profiles that favor foam cell formation, but it is likely 
that components other than the FFA differentially affect macrophage gene expression.  
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Chapter 1: Introduction 
1.1 Atherosclerosis: A Chronic Arterial Disease 
1.1.1 Cardiovascular disease 
Cardiovascular disease (CVD) is a group of disorders, including coronary artery 
disease (CAD), cerebrovascular disease, rheumatic heart disease, peripheral arterial 
disease, congenital heart disease, and pulmonary embolism, which all affect the heart and 
blood vessels. Compared to other diseases, CVD is estimated to contribute a large 
proportion to worldwide morbidity and mortality rates. In 2008, CVD was reported to cause 
17.3 million deaths worldwide, with CAD alone contributing about 7.4 million deaths (1). 
The number of CVD deaths is expected to rise above 23.6 million by 2030 (2). Two major 
factors that have been implicated in the development of CVD are behavioral and metabolic 
risk factors. Behavioral risk factors include unhealthy diet and physical inactivity, whereas 
metabolic risk factors include increased blood lipids, blood sugar, and blood pressure (1). 
1.1.2 Overview of atherosclerosis 
 The underlying pathological process occurring in the arterial walls which results in 
CAD is termed atherosclerosis. Atherosclerosis is an arterial disease where, due to lipid 
accumulation, a plaque builds up within the arteries and restricts the oxygen-rich blood 
supply to the heart and other parts of the body (Figure 1). Progression of this disease occurs   
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Figure 1: Schematic diagram of the proceses leading to atherosclerosis 
A triglyceride (TG)-rich lipoprotein, such as plasma very low-density lipoprotein (VLDL), 
is hydrolysed by lipoprotein lipase (LPL) bound to endothelial cells (EC). The hydrolysed 
lipoproteins tend to lose their lipid moiety and become smaller in size, forming low-density 
lipoprotein (LDL). This cholesterol-enriched lipoprotein enters the sub-endothelial space 
where it undergoes modifications, such as oxidation, thus triggering monocyte chemotaxis. 
The monocyte-derived macrophages in the sub-endothelial space uptake modified LDL 
(mLDL), leading to macrophage- derived foam cells. The smooth muscle cells (SMC) 
migrate to intima where they too uptake mLDL forming foam cells. The accumulation of 
lipid provokes a complex inflammatory response which ultimately leads to plaque rupture. 
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through a sequence of key steps (3). Notably, three key stages are involved in 
atherosclerosis: formation of a fatty streak, fibrous lesions, and complex lesions (4). 
Initially, lipoprotein retention within the sub-endothelial space of the arterial wall triggers 
various biological responses. Accumulated lipoproteins can become oxidized, thus 
provoking inflammatory responses, such as monocyte chemotaxis, cytokine production, 
and T-lymphocyte recruitment (4,5). The monocytes recruited into the sub-endothelial 
space are differentiated into macrophages, a major immune cell type found in 
atherosclerotic tissue (4,5). The oxidized lipoproteins and, in particular, the low-density 
lipoproteins (LDL) in the sub-endothelial space are internalized by macrophages through 
scavenger receptors (6,7). However, Moore et al. (8) have shown that macrophage cells 
accumulated lipids and promoted atherosclerosis in the absence of scavenger receptors, 
suggesting that additional mechanisms are also involved in lipid uptake. Subsequent 
studies by Kruth et al. (9,10) have shown that macrophages also accumulate native LDL 
through a process called macropinocytosis. The internalized lipoproteins are further 
hydrolysed by lysosomal acid lipase, a lysosomal enzyme present in late endosomes, 
liberating lipids that can contribute to macrophage foam cell formation that plays an 
important role in the progression of atherosclerosis (11). The lipid loaded macrophages 
also trigger the migration of smooth muscle cells into the intima, that leads to the secretion 
of collagen and matrix proteases (12). In addition, smooth muscle cells also contribute to 
foam cell progression by their ability to accumulate lipids (12). These lipid laden cells 
collectively appear as a yellow streak in the arterial wall (4). No chronic symptoms are 
noticed at this stage (3). Over several years, a fibrous cap covers the smooth muscle cells 
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and lipid laden macrophage cells, which are susceptible to rupture at later stages (3). In 
addition, increased thickness of fibrous cap, calcification, microhemorrhage, thrombosis, 
and fissures were noticed at this complex stage (3-5). Moreover, aggregation of 
extracellular lipids in the intima results in the progression of atherosclerotic conditions, 
causing complex lesions. At this stage, an advanced inflammatory response is triggered, 
resulting in the apoptosis of foam cells, as well as necrosis, which can affect plaque 
stability. Plaque rupture usually occurs in lipid-rich macrophage-dense regions of the 
lesion. The apoptotic and necrotic foam cells release proteolytic enzymes that impair the 
fibrous cap, resulting in release of thrombotic molecules and increased vascular occlusion 
that further leads to stroke, myocardial infarction, and may even cause death (3-5). 
However, several fates are possible during all stages of atherosclerosis. For instance, a 
reduction in plasma cholesterol levels could possibly result in disease regression (13). 
Major lipid types that are found in atherosclerotic lesions are cholesterol, 
cholesteryl esters (CE), and phospholipids (PL) (14). All of these lipids originate from 
circulating lipoproteins, notably from LDL and remnant lipoproteins (15,16). The retention 
of lipoproteins in the arterial wall is enhanced by lipolytic enzymes, particularly lipoprotein 
lipase (LPL) bound to the endothelial cell surface (15,17). The role of LPL in 
atherosclerosis has been studied for several decades. LPL expression in certain tissues, 
such as heart, skeletal muscle, and adipose tissue, has been shown to play an 
atheroprotective role by hydrolyzing triglyceride (TG)-rich lipoproteins and by increasing 
high-density lipoprotein (HDL) levels in the plasma (18-20). In contrast, several pieces of 
evidence support the notion that macrophage LPL could promote atherosclerosis (15,21-
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24). In addition, Mamputu et al. (25) and Obunike et al. (26) have shown that LPL anchored 
to the endothelial cell surface induces monocyte adherence, thus promoting foam cell 
formation. The LPL bridging function has also been shown to enhance monocyte adhesion 
to bovine aortic endothelial cells, suggesting a possible pathophysiological role of LPL 
(25). Furthermore, the lipolytic products generated through lipoprotein hydrolysis by LPL, 
such as free fatty acids (FFA), can provoke several cytotoxic events involved in plaque 
formation (27).   
1.2 Overview of Lipoproteins and their Metabolism 
 A lipoprotein is a complex particle that contains both lipid and protein. It plays a 
crucial role by transporting hydrophobic lipids within the aqueous environment of the 
circulation to peripheral tissues. Based on their density, lipoproteins are classified into five 
major classes: chylomicrons (ρ<0.94 g/ml), very low-density lipoproteins (VLDL) 
(ρ<1.006 g/ml), intermediate-density lipoproteins (IDL) (ρ=1.006-1.019 g/ml), LDL 
(ρ=1.019-1.063 g/ml), and HDL (ρ=1.063-1.21 g/ml) (28). These complex particles contain 
TG and CE in their hydrophobic core, surrounded by a PL monolayer embedded with 
cholesterol and apolipoproteins. Although lipoprotein classes share the same elementary 
structural traits, each class has a distinct size range, as well as distinct proteins and lipids 
which further determine the function of each class (29,30).  
 An apolipoprotein is a protein that combines with lipid to produce lipoproteins. 
Their distribution plays a crucial role in determining the structure of lipoproteins. Most 
apolipoproteins have an amphipathic alpha helix structure, where the hydrophilic amino 
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acid residues are exposed to the aqueous circulation, and the hydrophobic amino acid 
residues interact with the lipoprotein lipids. Most of the apolipoproteins have the ability to 
solubilize neutral lipids in the circulation. In addition, some apolipoproteins also have 
flexible regions that help them to change their conformation according to the lipid 
composition in the lipoprotein and also according to different lipoprotein transformation 
forms in the circulation. Furthermore, some apolipoproteins play a key role in receptor 
recognition and in regulating key enzymes involved in lipoprotein metabolism (30).     
 Each major class of lipoproteins has an individual role in transporting lipids in the 
circulation. Exogenous TG obtained from the diet are packed with a truncated 
apolipoprotein, termed apoB48, cholesterol, CE, and PL to form chylomicrons in the 
enterocytes of the small intestine (31). Once a chylomicron is synthesized in the intestine, 
it is transported via the lymphatic system into the circulation, where LPL that is attached 
to the luminal surfaces of the capillary endothelium can hydrolyse the TG molecules of the 
chylomicron. On the other hand, endogenous TG synthesized in the liver is packed with 
apoB100, cholesterol, CE, and PL to synthesize VLDL (31). Similar to chylomicrons, 
VLDL that is synthesized in the liver also enters the circulation, where LPL anchored to 
the capillary endothelium hydrolyses molecules on VLDL, thereby liberating fatty acids 
for tissue utilization. After hydrolysis by LPL, both chylomicron and VLDL particles 
becomes smaller and denser in the circulation forming chylomicron remnants and IDL. 
Chylomicron remnants are removed from the circulation by the liver through a process that 
is mainly facilitated by the apolipoprotein apoE that is carried by the remnants (32). IDL 
synthesized in the circulation is mainly hydrolysed by hepatic lipase (HL) to form LDL or 
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removed from the bloodstream by the liver via receptor-mediated endocytosis (33,34). The 
LDL particles are taken up by peripheral cells through the LDL receptor (LDLR) where 
the cholesterol components of the LDL are utilized for the synthesis of steroid hormones 
and maintenance of cellular membranes. In addition, the liver also removes some LDL 
particles from the circulation through receptor-mediated endocytosis to prevent excess 
LDL in the bloodstream. This process of transporting lipoprotein lipids to the peripheral 
tissue is termed forward lipid transport. Except HDL, all other lipoproteins are involved in 
this process (Figure 2) (35). 
 HDL is involved in reverse cholesterol transport (RCT), a process that involves the 
net movement of cholesterol from non-hepatic tissues to the liver. The mechanism involved 
in RCT was first postulated by Glomset in 1968 (36). The major apolipoprotein component 
present in HDL is apoA-I; it is initially synthesized and secreted with little association to 
lipid from the intestine and the liver. The apoA-I accepts cholesterol and PL extracellularly 
from the peripheral cells to form pre-beta HDL, which is a HDL precursor that is discoidal 
in shape (37,38). The cholesterol and PL are transported from peripheral cells by the 
adenosine triphosphate-binding cassette transporter, sub-family A, member 1 (ABCA1) 
(39). Aiello et al. (40) have shown that the deletion of ABCA1 in macrophages caused 
severe foam cell accumulation in apoE-null mice. However, the absence of ABCA1 did 
not affect plasma HDL levels. In addition to ABCA1, adenosine triphosphate-binding 
cassette transporter, sub-family G, member 1 (ABCG1) and scavenger receptor type-BI 
(SR-BI) are also involved in transporting cholesterol from peripheral cells to nascent HDL  
9 
 
 
 
 
Figure 2: Schematic representation of lipoprotein metabolism 
The exogenous and endogenous triglyceride (TG) molecules are packed into chylomicrons 
and very low-density lipoproteins (VLDL) in the intestine and the liver. These TG-rich 
lipoproteins are transported into the circulation where they are preferentially hydrolysed 
by LPL to yield free fatty acids (FFA) for tissue utilization. Due to the hydrolysis of TG 
and phospholipid (PL), the chylomicron and VLDL become smaller and denser forming 
chylomicron remnants and intermediate density lipoprotein (IDL). Chylomicron remnants 
are cleared from the circulation by the liver where they are utilized for many biological 
processes, including VLDL synthesis. IDL formed in the circulation are further hydrolysed 
by hepatic lipase (HL) to liberate FFAs. Due to the loss of TG/PL molecules in IDL, they 
become smaller in size forming a cholesterol-enriched LDL in the circulation. The 
cholesterol particles in LDL are taken up by tissues for use in numerous processes. In 
addition, LDL is cleared from the circulation by the liver through receptor-mediated 
endocytosis. When excess cholesterol is present in the peripheral cells, apolipoprotein A-I 
(apoA-I) accepts cholesterol and PL from the cells through adenosine triphosphate-binding 
cassette transporter, sub-family A, member 1 (ABCA1), forming pre-beta high-density 
lipoprotein (HDL). In addition, two other lipid transporters namely, adenosine 
triphosphate-binding cassette transporter, sub-family G, member 1 (ABCG1) and 
scavenger receptor type-BI (SR-BI), also transport cell cholesterol and PL to pre-beta 
HDL. The free cholesterol in the nascent HDL is esterified by lecithin:cholesterol 
acyltransferase (LCAT), forming mature HDL. The cholesteryl ester (CE) of HDL is 
removed from the bloodstream in two ways: 1) HDL exchanges its CE for TG that is 
present in VLDL, IDL and LDL with the help of CE transfer protein (CETP), which is 
ultimately removed from the circulation by VLDL/LDL receptors in the liver; and 2) 
mature HDL is hydrolysed by HL and endothelial lipase (EL) that are anchored to cell 
surfaces, thereby liberating apoA-I and CE. The liver also uptakes HDL CE via SR-BI; 
lipid-poor apoA-I that is generated in this process can be reused for reverse cholesterol 
transport.  
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(41,42). These cholesterol transporter expression levels are shown to be regulated by 
different nuclear receptors. For instance, peroxisome proliferator-activated receptor 
(PPAR)-γ combined with liver X receptor (LXR)-α have been shown to regulate ABCA1 
expression in THP-1 macrophages and inactivating the PPAR-γ gene in macrophages 
increased atherosclerosis in LDLR-null mice (43). 
 The cholesterol acquired by pre-beta HDL is initially in an unesterified form. 
Lecithin:cholesterol acyltransferase (LCAT) binds to the apoA-I component of pre-beta 
HDL and transfers one acyl group from lecithin (or phosphatidylcholine) to unesterified 
cholesterol in order to produce CE and lysolecithin (or lysophosphatidylcholine) (36). This 
catalyzed reaction is vital for accepting more free cholesterol from peripheral cells (36). 
Newly formed CE moves to the hydrophobic core of the nascent HDL and eventually 
makes mature HDL. Although LCAT is crucial for mature HDL formation and the increase 
in plasma HDL levels, an overexpression of LCAT in mice fed a cholesterol-rich diet did 
not reduce atherosclerosis (44,45). In addition to LCAT, PL transfer protein (PLTP) also 
plays an important role in mature HDL formation by transferring phospholipids from 
apoB100-containing lipoproteins to HDL (46). A study showed that C57BL/6 mice 
overexpressing human PLTP had increased pre-beta HDL formation and decreased plasma 
HDL cholesterol levels compared to wild-type mice, suggesting potential anti-atherogenic 
effects of PLTP (47).  
  The mature HDL removes extrahepatic CE in two different ways. Some of the CE 
in HDL is transferred to apoB-containing lipoproteins in exchange for TG molecules with 
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the help of CE transfer protein (CETP). The liver clears CE molecules in apoB-containing 
lipoproteins through receptor-mediated endocytosis. Although CETP-mediated CE transfer 
is also a part of RCT, a deficiency of this protein in humans leads to increased HDL levels 
and reduced catabolism of apoA-I (48). TG-enriched HDL formed by CETP undergoes 
hydrolysis by HL that is bound to the sinusoidal capillaries of the liver surface and 
endothelial lipase (EL) that is bound to the vascular endothelium (49,50). The remodeling 
of HDL by HL and EL liberates HDL remnant particles and lipid-poor apoA-I (49). The 
HDL remnant particles are internalized and degraded by putative receptors in the liver 
(37,51). Also, SR-BI expressed on the liver binds to apoA-I of the mature HDL and 
promotes selective uptake of CE, which can be further processed by the liver into bile for 
excretion (52). The lipid-poor apoA-I liberated from HDL initiates RCT again by accepting 
free cholesterol from peripheral cells (37).  
1.3 The sn-1 Lipases: Tissue Profiles, Substrate Specificities, and Physiological Roles 
The key enzymes that constitute the sn-1 lipase family are LPL, HL, and EL. These 
enzymes release fatty acids by hydrolyzing the ester bonds at the sn-1 position of the TG 
and PL components of circulating lipoproteins (53). The sn-1 lipases are heparan sulfate 
proteoglycan-binding enzymes that are usually bound to the endothelial cell surface (53). 
In addition, these enzymes also possess a bridging function that is independent of their 
catalytic function (54-56). The bridging function of sn-1 lipases allows them to bring 
plasma lipoproteins very close to cell surface receptors to promote lipoprotein uptake into 
cells (57). All three enzymes have a common ancestral origin, as they share similar 
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sequences at both the DNA and protein levels (57). However, sn-1 lipases have different 
substrate specificities and tissue expression profiles, suggesting that the different lipases 
emerged for unique physiological functions (53).  
The sn-1 lipases exhibit distinct tissue expression profiles. LPL expression in many 
species, including humans, has been observed in adipose tissue, mammary glands, spleen, 
heart, skeletal muscles, and lungs (58-62). HL expression has been previously reported in 
ovaries, adrenal tissues, and hepatocytes of rat and humans (63-65). EL expression has 
been reported in the placenta, thyroid, lungs, kidneys, hepatocytes, and macrophages of 
mice and humans (66). EL is initially synthesized in arterial/venal endothelial cells and is 
anchored to the luminal surface of the capillary endothelium, exposing itself to the 
bloodstream to perform its biological function (49,66).  
With respect to substrate specificity, LPL predominantly hydrolyses TG and EL 
preferentially hydrolyses PL in circulating lipoproteins (67). HL shows equal preferences 
for both TG and PL in lipoproteins (67). LPL principally hydrolyses TG molecules in 
chylomicrons and VLDL, and reduced LPL activity was reported to induce severe 
hypertriglyceridemia and cause death in LPL-null mice (68). Also, low levels of LPL have 
a negative impact on HDL levels (68,69). EL is involved in preferentially hydrolyzing PL 
from HDL, and this is inversely associated with HDL levels (70,71). Recently, 
Miksztowicz et al. (72) have shown that EL is accountable for low levels of HDL in chronic 
kidney disease patients. HL is primarily involved in hydrolyzing TG and PL from all 
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lipoproteins (73,74). HL activity has been shown to positively correlate with small dense 
LDL levels and negatively correlate with HDL levels (75,76).  
Several lines of evidence suggest that sn-1 lipases may play a vital role in 
atherosclerosis. Tissue-specific expression of LPL determines its crucial role in 
atherosclerosis. For instance, LPL expression in adipose tissue and muscle contribute to 
apoB-containing lipoprotein clearance, therefore suggesting that LPL has anti-atherogenic 
properties (18,20). In contrast, compelling evidence from in vitro and in vivo studies have 
shown that macrophage LPL exhibits pro-atherogenic properties (15,21-24,77).  
Similar to LPL, anti-atherogenic and pro-atherogenic actions of HL could depend 
on where it is expressed. Hepatic HL increases TG-rich lipoprotein clearance from the 
bloodstream, suggesting HL could possess anti-atherogenic properties (78,79). However, 
studies on murine models had shown contradictory results with respect to the role of HL in 
atherosclerosis (80,81). 
A clinical study by Badellino et al. (82) reported that EL activity positively 
correlates with coronary artery calcification. Also, immunohistochemical analysis and 
double label immunofluorescence confirmed that EL is expressed within human 
atheromatous plaques (83). These studies suggest that EL might have a unique role in 
atherosclerosis. However, a study on the loss-of-function and gain-of-function of EL on 
THP-1 macrophages showed that EL overexpression promoted apoA-I-mediated 
cholesterol efflux and EL suppression reduced apoA-I-mediated cholesterol efflux (84). 
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The role of HL and EL in atherosclerosis is not clearly known and requires further 
clarification. 
1.4 Characteristics of LPL 
1.4.1 LPL genetics and structure 
 The human LPL gene is found on chromosome 8p22, spanning about 30,000 base 
pairs in length with 10 exonic regions and encodes for mature LPL that contains 448 amino 
acids (85). A putative three-dimensional model of LPL that was proposed based upon 
crystal structure of pancreatic lipase showed that LPL contains a larger N-terminal domain 
and a smaller C-terminal domain that are structurally distinct and connected by a flexible 
linker region (86-88). Studies have shown that the N-terminal domain of human LPL 
contains a binding site for heparan sulfate at residues 279-282 and 292-304, a highly 
conserved catalytic triad (Ser132, Asp156, and His241), an apoC-II interaction site at 
Lys147/Lys148, and a polypeptide ‘lid domain’ at residues 216-239 that covers the catalytic 
cleft and is essential for lipolysis (89-91). In addition, it also contains a β5 loop that is 
required for binding lipid substrates (89). The C-terminal domain is necessary for binding 
lipoprotein substrates (89). Wong et al. (92) previously showed that LPL monomers are 
organized in a head-to-tail orientation to form active homodimers. However, dissociation 
of native homodimers to monomers has been shown to permanently inactivate LPL 
catalytic function (93).  
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1.4.2 Synthesis and secretion of LPL 
The nascent polypeptide chain translated from the LPL mRNA is not catalytically 
active until it undergoes a sequence of post-translational modifications. Studies have 
shown that mature LPL can occur as various glycoforms (94-96). The newly synthesized 
polypeptide chain is subjected to N-glycosylation and two important oligosaccharide 
processing events: 1) trimming of glucose residues by glucosidases; and 2) trimming of 
high mannose chain by mannosidases, in the endoplasmic reticulum (ER). Ben-Zeev et al. 
(97) have shown that inhibition of glucose trimming in mutant Chinese hamster ovary cells 
decreased LPL activity and secretion; however, blocking mannose trimming did not affect 
LPL activity or secretion. Therefore, their results suggest that the trimming of the terminal 
glucose residues in the N-linked oligosaccharide moiety of LPL by glucosidases is 
responsible for acquisition of LPL catalytic activity. The glycosylated LPL protein 
becomes an active homodimer in the presence of lipase maturation factor 1, a chaperone 
that is involved in properly folding and assembling lipases in the ER (98). Overexpression 
of lipase maturation factor 1 has been shown to increase the LPL activity in adipose and 
muscle tissues (99). Next, the active LPL is transported from the ER to different 
compartments of the Golgi complex where it is fully processed. The mature LPL is 
transported either to lysosomes or heparan sulfate proteoglycans (HSPG) on the cell 
surface (Figure 3). 
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Figure 3: Schematic representation of LPL synthesis, processing and transportation 
The LPL gene is transcribed in the nucleus of the parenchymal cell. The transcribed LPL 
undergoes translation and translational modifications, such as N-linked glycosylation and 
oligomerization in the endoplasmic reticulum. Properly folded and assembled active LPL 
homodimers (      ) are transported to the Golgi complex through vesicles. In contrast, 
inactive and misfolded LPL aggregates are subjected to degradation (100). Inside the Golgi 
network, the active LPL is received by the cis-Golgi network (CGN) which then transports 
the active LPL to the Golgi stack (GS) where the enzyme is further processed (       ). The 
active LPL is transported to the trans-Golgi network (TGN) where they undergo further 
processing. The mature LPL (    ) from TGN is either transported to heparan sulfate 
proteoglycans (HSPG) on the cell surface through vesicles or transported to lysosomes for 
degradation. LPL anchored to HSPG on the cell surface is further translocated to the 
luminal surface of capillary endothelium by glycosylphosphatidylinositol anchored high 
density lipoprotein binding protein 1 (GPIHBP1). LPL on the capillary endothelium 
hydrolyses triglyceride-rich lipoproteins (TRL).   
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The active LPL bound to HSPG on the parenchymal cell surface is further translocated 
through the interstitial space to the luminal surface of the vascular endothelium. However, 
the mechanism involved in translocating LPL onto the HSPG bound to the luminal surface 
of the capillary endothelium is not very clear. Glycosylphosphatidylinositol anchored high 
density lipoprotein binding protein 1 (GPIHBP1), a GPI-anchored protein, has been shown 
to transport LPL onto the luminal surface of capillary endothelial cells using a GPIHBP1-
null mouse model (101). This study clearly showed that the absence of GPIHBP1 protein 
results in impaired LPL lipolytic activity. 
1.4.3 Biological functions of LPL 
LPL, previously known as ‘clearing factor’, is an extracellular lipase enzyme that 
plays a crucial role in lipid metabolism (102). Due to their larger size, chylomicrons and 
VLDL cannot directly pass through the capillary endothelium in different tissues. Thus, 
LPL is bound to negatively charged HSPG on the luminal side of capillary endothelial cells 
and acts to hydrolyse these TG-rich lipoproteins. However, homodimeric LPL has to be 
initially activated by a cofactor before it can perform its catalytic function. The apoC-II 
component of chylomicrons and VLDL acts as a specific LPL cofactor that is required for 
the activation of LPL on the cell surface (103). The active LPL then hydrolyses lipid 
components of lipoproteins to produce non-esterified fatty acids, which are utilized by 
tissues for various biological processes.  
Eisenberg et al. (104) had suggested that lipoprotein lipid hydrolysis by LPL could 
occur through a series of attachment and detachment events. Moreover, experiments 
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conducted by Saxena et al. (105) and Vilella et al. (106) reported that LPL could detach 
itself from the capillary endothelium cell surface and attach with remnant lipoproteins in 
the circulation. The displaced LPL is replaced by newly synthesized LPL on the cell 
surface.  
Like other sn-1 lipases, LPL also possesses a non-catalytic bridging function 
independent of its catalytic function. Eisenberg et al. (56) reported that LPL binds 
simultaneously to both lipoproteins and HSPG on the cell surface. In addition, several 
studies have shown that LPL interacts with members of the LDLR gene family, such as 
LDLR, the VLDL receptor, the LDLR-related protein 1 and glycoprotein 330 (107). This 
LPL-receptor interaction allows the cell to uptake lipoproteins effectively.   
1.4.4 The regulation of LPL expression and activity 
1.4.4.1 Transcriptional control of LPL 
Numerous cis-acting elements are present in the 5’ regulatory region of the LPL 
gene and these are vital for the regulation of LPL promoter activity. For instance, Yang et 
al. (108) have shown that 5’-CCTCCCCCC-3’, a conserved sequence motif in the LPL 
regulatory region, can bind with transcription factors such as specificity protein (Sp) 1 and 
Sp3, and positively regulate basal promoter activity. Also, Sp1 interacts with sterol 
regulatory element binding protein-1 to synergistically activate the LPL promoter. In 
contrast, the same study also showed that a T to G substitution within the LPL regulatory 
region can suppress the promoter activity (108). 
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PPAR-α, -δ, and −γ have also been shown to regulate LPL gene expression in a 
tissue-specific manner by interacting with the PPAR response element site in the LPL 
promoter. PPAR-α was shown to regulate LPL gene expression in the rat liver, while 
PPAR-γ was shown to increase the LPL mRNA expression in rat adipose tissue (109). In 
addition, Blanchard et al. (110) reported that PPAR-γ activation induces LPL gene 
expression in rat adipose tissue through the mammalian target of rapamycin signaling 
pathways. In contrast, PPAR-δ is a VLDL sensor that increases LPL gene expression and 
lipid accumulation in murine macrophage cells (111). Numerous chemical compounds, 
including fatty acids, are reported to activate PPARs and LPL gene transcription (112,113). 
With respect to other nuclear receptors, LXR was shown to predominantly induce 
LPL expression in in macrophage cells and the liver of mice fed with high cholesterol diet, 
but it did not regulate LPL gene expression in adipose tissue or muscle (114). Moreover, 
cytokines are also involved in regulating LPL transcription. Tengku et al. (115) have shown 
that interferon γ and tumor necrosis factor (TNF)-α synergistically eliminate the LPL 
mRNA expression in murine macrophage cells. In addition, Morin et al. (116) reported that 
TNF-α inhibits LPL activity in adipocytes by eliminating the binding affinity of organic 
cation transporter-1 and nuclear factor-Y proteins in the CCAAT site of the LPL promoter. 
Also, Irvine et al. (117) reported that transforming growth factor (TGF)-β negatively 
regulates the expression of the LPL gene at the transcriptional level. 
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1.4.4.2 Translational and post-translational regulation 
LPL activity is regulated by various factors, including hormones, fatty acids and 
microRNAs (miR). Several studies have reported a correlation between decreased LPL 
activity and diabetes. For instance, Kraemer et al. (118) showed that LPL activity in rat 
adipose tissue is controlled by insulin through phosphatidylinositol 3-kinase and ribosomal 
protein S6 kinase signaling pathways. A subsequent study by Ranganathan et al. (119) 
reported that LPL translation is inhibited in the adipocytes of diabetic rats due to an 
interaction between a cytoplasmic factor, likely RNA-binding protein, and specific 
nucleotide sequences of the 3̍- untranslated region of LPL. Other hormones, including 
thyroid hormone and epinephrine, have been shown to regulate LPL activity in rat adipose 
tissue (120,121). As well, an accumulation of FFA (in particular, unsaturated fatty acids) 
at the endothelial cell surface was shown to cause LPL dissociation in vitro, thereby 
suggesting the impact of fatty acids in regulating LPL activity (105,122). Recent studies 
also established the role of miRNAs in regulating LPL activity. For example, inhibiting 
miR-467b expression in mouse hepatocytes increased LPL mRNA and protein levels, 
suggesting that miR-467b post-transcriptionally regulates LPL expression (123). Also, 
Tian et al. (124) reported that apoE-null mice injected with a synthetic miR-467b molecule 
showed inhibition of both LPL mRNA and protein levels in the aorta. In addition, LPL 
activity is also regulated by several interactive proteins, including angiopoietin-like 
proteins. For example, Bergo et al. (125) and Sukonina et al. (126) have previously shown 
that angiopoietin-like protein 4 inhibits LPL by turning active homodimers into inactive 
monomers in murine adipose tissue during the fasting state. 
23 
 
1.5 Macrophage LPL in Atherosclerosis 
 The evidence for a pro-atherogenic role of macrophage LPL was strongly 
reinforced by rodent studies. Zilversmit et al. (15) first reported that aortic LPL activity 
increases in correlation with cholesterol accumulation and CE influx into the aorta of 
cholesterol-fed rabbits, suggesting that LPL in the arterial wall may contribute to 
atherosclerosis. Subsequently, several rodent studies provided strong evidence for a pro-
atherogenic role of macrophage LPL. For instance, peritoneal macrophages isolated from 
inbred murine strains that were susceptible or resistant to atherosclerosis showed that 
susceptible murine strains have higher LPL expression in comparison to resistant strains 
(127). Upon being fed a cholesterol-rich diet for three months, C57BL/6 mice transplanted 
with LPL-null mouse bone marrow showed a reduction in serum cholesterol levels, apoE 
levels, and aortic lesion area compared to wild-type mice, which suggested that a blockade 
of macrophage LPL minimizes lesion development in mice (128). Supporting this work, 
Babaev et al. (22) transplanted C57BL/6 mice with either LPL-/- or LPL+/+ fetal liver cells, 
a source of hematopoietic cells, to study the role of macrophage LPL in foam cell 
formation. Their study reported that recipients of LPL-/- cells fed an atherogenic diet had a 
55% decreased mean aortic lesion area compared to mice that received LPL+/+ fetal liver 
cells. In addition, subsequent studies on LDLR-null mice transplanted either with LPL-/- or 
LPL+/+ macrophages also showed that mice that received LPL-/- cells had a 69% reduced en 
face aortic lesion area compared to LPL+/+ recipients (21). The transgenic overexpression 
of LPL in mice also led to increased atherosclerosis: Wilson et al. (23) reported that male 
apoE-null mice expressing macrophage-specific human LPL and fed a Western diet for 
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eight weeks displayed increased occlusion in the aortic sinus region compared to control 
mice. Wu et al. (129) also showed that the adenoviral expression either catalytically active 
human LPL or inactive LPL in balloon-injured rabbit carotid arteries enhanced lipid 
accumulation in arteries, suggesting that even catalytically inactive LPL enhances 
atherosclerosis lesion formation, likely through its binding ability. In addition to lipid 
deposition, adenoviral gene transfer of both active and inactive human LPL in endothelial 
intact-carotid arteries of apoE-null mice enhanced vascular cell adhesion molecule-1 
expression (130). Recently, Takahashi et al. (131) reported that peritoneal macrophages 
isolated from macrophage-specific LPL knockout (generated using Cre-loxP gene 
targeting) and apoE double knockout mice had less accumulation of CE and TG compared 
to control mice. In addition, the authors also observed low levels of cluster of 
differentiation 36 (CD36) and carnitine palmitoyltransferase-1 gene expression in double 
knockout mice macrophages incubated with VLDL in comparison to macrophages from 
apoE-null mice (131). Together, these in vivo studies suggest that arterial wall LPL, likely 
derived from macrophages, have a pro-atherogenic effect. 
In vitro studies also support the notion that LPL expression in macrophages causes 
foam cell formation. A previous study showed that LPL hydrolyses VLDL (isolated from 
normolipidemic donors) in a saturable manner and causes accumulation of TG and CE in 
J774 macrophages (132). LPL has been previously shown to increase the uptake and 
degradation of LDL in THP-1 macrophages, independent of the LDLR (133). In addition, 
LPL has been shown to preferentially uptake mildly oxidized LDL and VLDL compared 
to heavily oxidized lipoproteins in THP-1 macrophages via an unknown mechanism (134). 
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Recently, Kawashima et al. (24) showed that the downregulation of LPL expression in 
THP-1 macrophages increased ABCA1 gene expression and ABCA1-dependent 
cholesterol efflux, suggesting an inverse relationship between macrophage LPL and 
ABCA1 cholesterol transporter expression levels. In support of this, Yang et al. (77) 
showed that hydrolysis products that are generated by LPL downregulate the expression of 
ABCA1 and cholesterol efflux from THP-1 macrophages. Together, these studies suggest 
LPL induces lipid accumulation in macrophages and may have a pro-atherogenic effect.   
1.6 LPL Hydrolysis Products: FFA Components and their Pro-atherogenic Effects 
 The LPL-mediated hydrolysis of lipoprotein lipids in macrophages and smooth 
muscle cells was shown to liberate FFA, which may contribute to atherogenesis. For 
example, mice overexpressing human LPL in aortic smooth muscle cells were shown to 
induce FFA generation by 69% compared to their control mice and the FFA liberated by 
LPL also triggered vascular dysfunction by activating nicotinamide adenine dinucleotide 
phosphate-oxidase in a protein kinase C-dependent manner (135). Thus, this finding 
suggests that LPL hydrolysis products, independent of LPL, may also play a role in 
atherosclerosis. Interestingly, an in vivo study also showed that lipoprotein-derived fatty 
acids are taken up by two different pathways in the heart by using three mice models: 
CD36-null mice, heart-specific LPL knockout mice, and CD36-null mice without heart 
LPL (119). Their results showed that VLDL-derived fatty acids are taken up via a CD36-
mediated pathway and chylomicron-derived fatty acids are taken up via non-CD36 
pathways (136). 
26 
 
In vitro studies had reinforced the notion that the hydrolysis products liberated from 
lipoprotein lipids by LPL, and in particular the FFA, may potentially trigger foam cell 
formation. Previously, it was reported that the FFA components within LPL hydrolysis 
products increase the phosphorylation of Akt in THP-1 macrophages and induces lipid 
accumulation partly by modulating the phosphatidylinositide 3 kinase signaling pathway 
(137,138). In addition, Yang et al. (77) have previously shown that the FFA components 
within LPL hydrolysis products impair apoA-I mediated cholesterol efflux by modulating 
the gene expression levels of nuclear receptors and cholesterol transporters in THP-1 
macrophages. Using Raman spectroscopy, Hartigh et al. (139) showed that TG-rich 
lipoprotein hydrolysis by LPL enhances lipid droplet formation in THP-1 monocytes. In 
particular, the hydrolysis of postprandial VLDL by LPL led to more intense spectroscopic 
signals for lipid droplets in macrophages compared to hydrolysis products from preprandial 
VLDL that were generated by LPL. The authors also showed that saturated fatty acids 
(SFA) within the hydrolysis products induced a greater accumulation of lipid droplets in 
THP-1 monocytes compared to monounsaturated fatty acids (MUFA) and polyunsaturated 
fatty acids (PUFA) (139). Taken together, these observations also suggest FFA species 
liberated by LPL could be potentially pro-atherogenic. 
In addition to lipid accumulation, previous studies have also shown that LPL 
hydrolysis products, and especially the FFA species, may act as an inflammatory mediator, 
thereby affecting cellular homeostasis. Eiselein et al. (140) reported that lipolytic products 
generated from TG-rich lipoproteins by LPL increased endothelial layer permeability in 
human aortic endothelial cells (HAEC) by rearranging the actin cytoskeleton organization, 
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by affecting junction protein localization and by stimulating caspase-3 activity. In their 
subsequent study, the authors also showed that LPL hydrolysis products enhances a stress 
response protein, activating transcription factor (ATF) 3, through the transforming growth 
factor-β1 signaling pathway in HAEC and, thus, suggesting that the hydrolysis products 
liberated by LPL enhances pro-inflammatory responses that may contribute to 
atherogenesis (141). Wang et al. (142,143) showed that LPL hydrolysis products generated 
from TG-rich lipoproteins enhance reactive oxygen species production in HAEC. 
Furthermore, the authors showed that the FFA components from LPL hydrolysis products 
stimulated TNF-α and the intracellular adhesion molecule expression level in HAEC (143). 
Taken together, these studies suggest that LPL hydrolysis products, particularly the FFA, 
may exert a critical role in atherogenesis. Although some studies have shown that the 
hydrolysis products liberated by LPL may play a pro-atherogenic role, a recent in vivo 
study reported that loss of fatty acid liberation from lipoprotein lipids by LPL enhances 
glucose oxidation and impairs cardiac function in the hearts of mice with a deletion of 
cardiac LPL (144). Thus, more studies are necessary to understand the role of LPL 
hydrolysis products in atherogenesis. Nonetheless, the effects of LPL hydrolysis products 
on differentially regulating macrophage gene expression are not yet established.  
1.7 Objectives 
The FFA liberated from total lipoprotein hydrolysis by LPL may act as bioactive 
lipids to differentially regulate the transcript profile of macrophages. Thus, the main 
objectives of my thesis are: 1) to identify differentially regulated genes in macrophages 
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treated with hydrolysis products generated from total lipoproteins by LPL using a human 
gene array; and 2) to study the effects of purified FFA or individual FFA classes on 
modulating the expression of select genes (based on microarray data) that may play a role 
in foam cell formation. I expect that the hydrolysis products (in particular, the FFA 
component) liberated from lipoproteins by LPL will increase the expression levels of genes 
associated with stress response, immune response, and lipid droplet formation. 
1.8 Hypothesis 
I hypothesize that the total lipoproteins hydrolysed by LPL will affect the gene 
expression in macrophages in a way that could potentially promote foam cell formation. I 
also hypothesize that the FFA components of LPL hydrolysis products will be responsible 
for modulation of select gene expression in macrophages to favor foam cell formation. 
1.9 Significance 
LPL expression in macrophages promotes atherosclerosis. Previous studies from 
our laboratory have shown that the FFA components of LPL hydrolysis products 
detrimentally affect the gene expression profile that is associated with macrophage 
cholesterol efflux (77). However, the complete effects of LPL hydrolysis products and its 
FFA components on macrophage gene expression and atherosclerosis are not fully 
understood. This study will provide new insights into the role of LPL hydrolysis products 
in altering macrophage transcript levels, and how these differentially regulated genes may 
contribute to foam cell formation. Understanding the impact of the FFA components of 
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LPL hydrolysis products on atherosclerosis will potentially highlight macrophage LPL as 
a therapeutic target in the future.   
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Chapter 2: Materials and Methods 
2.1 Mammalian Cell Culture  
2.1.1 HEK-293 cell culture and maintenance 
Human embryonic kidney (HEK)-293 cells (American Type Culture Collection, 
Manassas, VA, USA) were cultured in T75 flasks (BD Biosciences, Mississauga, ON, 
Canada) with Dulbecco's Modified Eagle Medium (DMEM) containing 4 mM L-
glutamine, 4.5 g/L glucose and 110 mg/L sodium pyruvate (#SH30243.01, HyClone, South 
Logan, UT, USA) and further supplemented with 10% v/v fetal bovine serum (FBS) (# 
SH30396.03, HyClone) and 1% v/v antibiotic/antimycotic (A/A) (HyClone). HEK-293 
cells were maintained at 37°C with 5% CO2(g). At 80-90% confluency, the cells were 
washed with 5 mL of DMEM media without both FBS and A/A. After washing, the cells 
were trypsinized with 2.5 mL of 0.25% (w/v) trypsin-ethylenediaminetetraacetic acid 
(EDTA) (#25200-056, HyClone) and incubated for 2 minutes at 37°C for the cells to detach 
from the surface. After incubation, 10 mL of DMEM media supplemented with 10% v/v 
FBS and 1% v/v A/A was added to the cells and mixed thoroughly.  Lastly, 1 mL of cells 
were added to a new flask containing 14 mL of DMEM media supplemented with 10% 
FBS and 1% A/A and incubated at 37˚C with 5% CO2(g). 
2.1.2 THP-1 cell culture and differentiation  
THP-1 monocytic cells (American Type Culture Collection) were cultured in 
Roswell Park Memorial Institute (RPMI)-1640 media containing 25 mM HEPES and 0.3 
mg/L L-glutamine (#SH30255.01, HyClone) which was further supplemented with 10% 
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FBS and 1% A/A (HyClone), and incubated at 37°C with 5% CO2(g). After 4 days of 
incubation, 3 mL of THP-1 cells (8 × 105 cells/mL) were added to a new T75 culture flask 
containing 12 mL of RPMI-1640 media with 10% v/v FBS and 1% v/v A/A, and 
maintained at 37°C with 5% CO2(g). 
 THP-1 cells were differentiated into macrophages when their concentration reached 
8 × 105 cells/mL.  The cells were added to 15 mL centrifuge tubes and spun down at 750 
rpm for 5 minutes. The supernatant was discarded and 10 mL of RPMI-1640 with 10 % 
v/v FBS and 1% v/v A/A was added to the pellets and mixed thoroughly. The cells were 
counted with a hemocytometer and 2.5 mL of 7.72 × 105 cells/mL were added to a 6-well 
plate with 100 nM of phorbol 12-myristate-13-acetate (PMA) (Sigma, St. Louis, MO, 
USA). After 48 hours of incubation, the cells were washed three times with RPMI-1640 
media without both FBS and A/A, and then incubated with RPMI-1640 media containing 
0.2% w/v fatty acid free-bovine serum albumin (FAF-BSA) (Sigma), 1% v/v A/A, 100 nM 
PMA. After 24 hours of incubation, the cells were washed once with RPMI-1640 media 
and incubated for 1 hour by supplementing RPMI-1640 media with 0.2 % w/v FAF-BSA, 
1% v/v A/A, 100 nM PMA and 25 µg/mL tetrahydrolypstatin (THL) (Sigma) – to inhibit 
endogenous lipase activity (145). After 1 hour, the THP-1 macrophages were treated with 
lipoprotein hydrolysis products, or FFA mixtures.  
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2.2 HEK-293 Transfection with Recombinant LPL Plasmid 
2.2.1 Human LPL plasmid generation 
Firstly, 100 μL of cultured Escherichia coli DH5α competent cells (Lucigen, 
Middleton, WI, USA) with transformation efficiency ≥ 1 × 1010 colony forming units per 
µg DNA were mixed with 1 µg of pcDNA3 containing the human LPL cDNA [GenBank: 
NM_000237] (pcDNA3.LPL, a kind gift from Dr. Daniel Rader, University of 
Pennsylvania, Philadelphia, PA, USA). The mixture was tapped gently and placed on ice 
for 30 minutes, then incubated at 42˚C for 90 seconds. The mixture was then placed on ice 
again for 10 minutes. A total of 900 μL of lysogeny broth (LB) (Sigma) was added to the 
mixture and the mixture was incubated at 37˚C in a MaxQ 4000 E-class shaker (Barnstead 
International, Dubuque, IA, USA) at 200 rpm for 90 minutes. Then, 200 µL of competent 
cells containing LPL plasmid were spread on 100-mm culture dishes (BD Biosciences) 
with LB agar (Fisher Scientific, Ottawa, ON, Canada) containing 100 µg/mL ampicillin 
(Sigma) and incubated for 18 hours at 37˚C. After incubation, a colony from the agar plate 
was picked and used to inoculate 5 mL of LB broth containing 5 µL of 100 µg/mL 
ampicillin in a 17 × 100 mm culture test tube (ThermoFisher Scientific). The cells were 
subsequently incubated at 37˚C, shaking at 200 rpm for 16 hours. After the incubation, the 
bacterial culture was centrifuged at 12,000 rpm using Legend Micro 21 R centrifuge 
(ThermoFisher Scientific) for 5 minutes at room temperature followed by removal of the 
supernatant. The pcDNA3.LPL plasmid was then extracted from the bacterial pellet using 
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the GeneJET plasmid miniprep kit (#K0502, ThermoFisher Scientific), according to the 
manufacturer's instructions. The purified plasmid was stored at -20˚C until used. 
2.2.2 HEK-293 cell transfection 
HEK-293 cells that had grown to 60-70% confluency were first washed with 5 mL 
of DMEM media and trypsinized (see section 2.1.1). After trypsinization, the cells were 
detached from the surface by incubating them at 37°C with 5% CO2 (g). After 2 minutes of 
incubation, 21 mL of DMEM media with 10% v/v FBS and 1% v/v A/A was added to the 
cells in the T75 flask. The cells were mixed thoroughly and 10 mL of cells were seeded in 
two 100-mm tissue culture dishes (BD Biosciences), and incubated for 24 hours. After the 
24 hours, cells were transfected with LipofectamineTM (Invitrogen, Burlington, ON, 
Canada) containing 5.85 μg of pcDNA3.LPL (see section 2.2.1) or LipofectamineTM 
without LPL plasmid (mock control). After 5 hours, 2X DMEM growth media (DMEM 
media supplemented with 20% v/v FBS and 2% v/v A/A) was added to the cells. At 24 
hours following the start of transfection, the cells were washed with 5 mL of plain DMEM 
and then treated with 5 mL of DMEM media containing 1% v/v A/A, and 10 U/mL heparin 
(Organon, Toronto, ON, Canada) to displace LPL from the cell surface. After 23.5 hours 
of incubation, the cells were further treated with 1 mL of DMEM containing 100 U/mL 
heparin and 1% v/v A/A, and cells were subsequently incubated for 30 minutes at 37°C 
with 5% CO2 (g). After incubation, the heparinized media from both the plates was removed 
and centrifuged in 15 mL tubes at 1,050 rpm for 5 minutes in an IEC HN-SII centrifuge 
(International Equipment Company, Nashville, TN, USA) to remove cell debris. The media 
containing LPL was aliquoted in 1.5 mL tubes and stored at -80˚C. The cells were washed 
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with 1X phosphate-buffered saline (PBS) prepared from 10X PBS containing 5.24g of 
NaH2PO4, 23 g of Na2HPO4, and 87.68 g of NaCl in 1 L distilled H2O (pH 7.4) and stored 
at -80˚C for immunoblot analysis.  
2.3 Qualitative and Quantitative Analysis of LPL 
2.3.1 Activity assay 
LPL activity was measured using 1,2-O-dilauryl-rac-3-glutaric-resorufin ester 
(#D7816-10MG, Sigma) as the substrate, as previously described by Lehner et al. (146) 
Briefly, a resorufin ester stock was prepared by dissolving 2 mg of resorufin ester in 1 mL 
of dioxane (Sigma) and stored at 4˚C until use. In a 96 well plate (ThermoFisher Scientific), 
in triplicate wells, 15 μL of heparinized media containing LPL or mock obtained from HEK 
transfection (see section 2.2.2) was added with 165 μL of lipase assay buffer (20 mM Tris, 
1 mM EDTA, pH 8.0). Next, 20 μL of 0.3 mg/mL resorufin ester, freshly prepared by 
diluting resorufin stock with lipase assay buffer, was added to each well containing LPL 
or mock samples. A Synergy fluorescent plate reader (Bio-Tek, Terrebonne, QC, Canada) 
was used to measure the absorbance at 572 nm over 60 minutes at 25˚C. The concentration 
of resorufin released was determined by using a standard curve, prepared by diluting 400 
μM resorufin ester stock to 0, 1, 2, 3, 4, 6, 10, 15, 20, 40 μM in 200 μL lipase assay buffer.  
2.3.2 Immunoblot analysis 
Transfected HEK-293 cells in 100-mm dishes were scraped with 1 mL of a 2X 
sample buffer (20% v/v glycerol, 0.125 M Tris-HCl, 5% v/v β-mercaptoethanol, 0.01% v/v 
bromophenol blue, 4% w/v sodium dodecyl sulfate (SDS), pH 6.8). Heparinized media (50 
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μL) from the transfected cells was mixed with equal volume of 2X sample buffer. Cell and 
media samples were then incubated for 5 minutes at 100°C. After incubation, proteins from 
20 μL of each sample were separated on a 10% SDS-polyacrylamide gel, using a Tris-
glycine-SDS buffer (25 mM Tris, 192 mM glycine, 0.1% w/v SDS, pH 8.3) (Bio-Rad, 
Mississauga, ON, Canada). Proteins were transferred onto a nitrocellulose membrane (Bio-
Rad) using a transfer buffer of Tris-glycine-SDS with 20 % v/v methanol (ThermoFisher 
Scientific). The transfer was carried out at 300 mA for 3 hours at 4˚C. After transfer, the 
membrane was incubated with a blocking solution of 5% bovine serum albumin (Sigma), 
0.05% v/v Tween-20 (Sigma), and 0.05% w/v NaN3 (ThermoFisher Scientific) in PBS on 
a rocking platform at room temperature.  After 2 hours of blocking, the membrane was 
subsequently incubated with a polyclonal anti-human LPL antibody (#sc-32885, Santa 
Cruz Biotechnology, Santa Cruz, CA, USA) in a 1:1,000 dilution with 5% bovine serum 
albumin (Sigma) for 3 hours at room temperature with rocking. After primary antibody 
incubation, the membrane was washed 4 times for every 10 minutes with PBS while 
rocking. Next, the membrane was incubated for 2 hours with a horseradish peroxidase-
conjugated anti-rabbit IgG in a 1:1,000 dilution with 5% bovine serum albumin (Sigma) 
(#SA1-200, Pierce Biotechnology, Rockford, IL, USA) at room temperature with rocking. 
Subsequently, the membrane was washed 4 times with PBS for 10 minutes with rocking. 
Finally, the membrane was developed with the ECLTM Prime chemiluminescent reagent 
(GE Healthcare, Baie d’Ufre, QC, Canada) according to manufacturer's instructions, and 
chemiluminescence was detected using an ImageQuant 4000 gel imager (GE Healthcare). 
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2.4 Lipoprotein Isolation and Quantification 
2.4.1 Total lipoprotein isolation 
As previously described, the total lipoproteins (ρ<1.21 g/mL) were isolated from 
the fasted plasma of healthy donors (by Dr. Robert Brown (Department of Biochemistry, 
Memorial University of Newfoundland), approval #11-109 by the Human Investigation 
Committee of Memorial University of Newfoundland). The blood (50-70 mL) was drawn 
in a 50 mL tubes and 0.2 M EDTA stock solution was added to each tube in order to have 
a final EDTA concentration of 2 mM. The blood was centrifuged at 2,800 rpm using a 
HeraeusTM MultifugeTM X1R centrifuge (ThermoFisher Scientific) for 15 minutes at 4˚C. 
After centrifugation, the plasma in the supernatant was pooled and the overall volume of 
plasma was measured. The density of plasma was exactly adjusted to 1.21 g/mL using a 
high density gradient solution prepared with 38.25 g of NaCl, 88.5 g of KBr, and 2.5 mL 
of 0.2 M EDTA. The adjusted plasma was transferred to ultracentrifuge tubes and subjected 
to ultracentrifugation using a Beckman L90K centrifuge with a 70.1Ti rotor (Beckman, 
Mississauga, ON, Canada) at 50,000 rpm for 44 hours at 4˚C.  After 44 hours, the top layer 
that contains total lipoprotein (yellow in color) was pipetted out into another tube and 
placed on ice. Meanwhile, cellulose dialysis tubing (ThermoFisher Scientific) was boiled 
in a beaker containing 500 mL of distilled water with 2% w/v NaHCO3 and 1 mM EDTA 
for 30 minutes. Next, the total lipoproteins were transferred into 13 cm cellulose membrane 
tubing and dialyzed against PBS for 24 hours (with PBS being changed every 6 hours) at 
4˚C. In order to avoid oxidation, the lipoproteins were stored under N2(g) at 4˚C after 
dialysis.  
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2.4.2 Phospholipid quantification in total lipoproteins 
The total lipoproteins were quantified using the Phospholipid C assay (Wako 
Diagnostics, Richmond, VA, USA) in a 96 well plate according to manufacturer’s 
instructions. Briefly, in triplicate, 5 μL of total lipoproteins were added to a well containing 
15 μL of PBS. A standard curve was created from a 300 mg/dL solution stock of 
phospholipid; using the stock, diluted working solutions (of 200 μL) of 5 mg/dL, 10 mg/dL, 
25 mg/dL, 50 mg/dL, 100 mg/dL, and 150 mg/dL were prepared using PBS. Then, 20 μL 
of each diluted concentration was added per well in the 96 well plate. Both lipoprotein 
samples and standard solutions were mixed with 200 μL of reagent and incubated for 5 
minutes at 37˚C. The absorbance of these samples was measured at 600 nm using a Synergy 
fluorescent plate reader (Bio-Tek).  
2.5 Lipoprotein Hydrolysis Product Generation, Quantification, and Incubation with 
THP-1 Macrophages 
2.5.1 Lipoprotein hydrolysis by LPL 
Lipoprotein hydrolysis products were generated as previously described (137,147). 
Briefly, the total lipoproteins, at a concentration of 3.5 mM (assessed using a phospholipid 
assay, see section 2.4.2), were mixed with in a 1:1 dilution ratio with either heparinized 
media containing LPL or heparinized media containing no LPL (mock) (obtained from 
HEK-293 transfections, see section 2.2.2) in 1.5 mL Eppendorf tubes. The mixtures were 
incubated at 37°C for 4 hours. After incubation, the samples were put on ice immediately. 
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The FFA liberated were quantified (see section 2.5.2). The hydrolysis products were used 
immediately to incubate THP-1 macrophages (see section 2.5.3).  
2.5.2 Lipoprotein hydrolysis product quantification 
FFAs liberated from the total lipoprotein hydrolysis by LPL were measured using 
the NEFA-HR(2) commercial kit (Wako). Firstly, 4 μL of LPL hydrolysis products or non-
hydrolysis products were added per well (in triplicate) to 96-well plates. Using a 
multichannel pipette, 225 μL of Solvent A from the kit was added to the samples and 
incubated for 10 minutes at 37˚C. After 10 minutes, 75 μL of Solvent B was added to the 
samples and incubated at 37˚C for 10 minutes. The absorbance was measured at 550 nm at 
37˚C using the Synergy plate reader. The concentration of FFA in each sample was 
determined by creating a standard curve from a stock solution containing 1 mM oleic acid; 
a total of 0, 0.5, 0.75, 1, 1.5, 2, or 4 μL of the stock solution was added into each well, and 
the volume in each well was brought to a final volume of 4 μL using distilled H2O.  
2.5.3 THP-1 macrophages treatment with lipoprotein hydrolysis product   
The LPL hydrolysis products (see section 2.5.1) were diluted to a concentration 
0.68 mM (which is a concentration that is comparable to those observed in the bloodstream 
in normophysiological conditions (148)) with RPMI-1640 media supplemented with 0.2% 
FAF-BSA, 1% A/A, 100 nM PMA, and 25 µg/ mL THL. Similar to LPL hydrolysis product 
volume, the non-hydrolysis products (0.03 mM) generated from mock transfection were 
also mixed with conditioned RPMI-1640 media. Following a 1 hour pre-treatment of   
THP-1 macrophages with THL (see section 2.1.2), the spent media from the cells was 
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removed and 930 µL of diluted LPL hydrolysis products or non-hydrolysis products were 
added to the THP-1 macrophage cells. After 18 hours of incubation, the media was 
removed and 1 mL of TRIzol® (ThermoFisher Scientific) was added to each well. The cells 
were mixed thoroughly in TRIzol® and transferred to 1.5 mL Eppendorf tubes, and stored 
at -80°C.  
2.5.3.1 Trypan Blue exclusion assay  
The viability of cells, following treatment with LPL hydrolysis or non-hydrolysis 
products, was assessed using Trypan Blue. Briefly, the macrophage cells that were 
subjected to the two different treatments were trypsinized using 500 μL of 0.25% (w/v) 
trypsin and incubated for 2 minutes at 37˚C to detach the cells from the tissue culture dish 
surface. The detached cells were further mixed with 1 mL of RPMI media supplemented 
with 10% FBS and 1% A/A, and then pipetted up and down several times to mix. In a 
separate tube, 30 μL of cell sample was mixed with 30 μL of 0.4% (w/v) Trypan Blue 
(Corning, NY, USA). The cells were loaded into a hemocytometer and both dead and live 
cells were counted in a defined area under the microscope. The following formula was used 
to calculate cell viability percentage: 
    Cell viability % =    Average of viable cells per treatment 
 
where, a total cell per square is the sum of viable and dead cells. 
  
Average of total cells per treatment 
× 100 (equation 1) 
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2.6. Incubation of FFA Mixture and Distinct FFA Classes with THP-1 Macrophages 
The concentrations of individual FFA species that are present in LPL hydrolysis 
products from total lipoproteins were previously quantified by our group (137). As 
previously described (77,137), a FFA mixture was prepared according to the amount of 
FFA liberated by LPL from the hydrolysis of total lipoprotein lipids. Palmitate (16:0), 
myristate (14:0), palmitoleate (16:1), oleate (18:1), sterate (18:0), linoleate (18:2), 
arachidonate (20:4) and docosahexaenoate (22:6) (all reagents from Nu-Chek Prep, 
Elysian, MN, USA) were dissolved to a concentration of 10 mg/ml using high performance 
liquid chromatography grade methanol and stored under N2(g) at -20°C until use. The total 
FFA mixture was prepared by removing 275.0 nmol of 16:0, 18.6 nmol of 14:0, 23.7 nmol 
of 16:1, 241.8 nmol of 18:1, 45.4 nmol of 18:0, 70.0 nmol of 18:2, 0.9 nmol of 20:4 and 
0.4 nmol of 22:6 from the stock solution. The methanol in the total FFA mixture was 
evaporated under N2(g) at 35°C and resuspended with 10 µL of dimethyl sulfoxide (DMSO). 
THP-1 macrophage cells, pre-treated with THL (see section 2.1.2), were further incubated 
with 990 µl of RPMI containing 0.2% w/v FAF-BSA, 1% A/A, 100 nM PMA, 25 µg/ml 
THL, and either the total FFA mixture or 10 µL of DMSO (vehicle control). The FAF-
BSA concentration was chosen because it is within the range observed within the aortic 
intima (149). FFA mixtures in DMSO, containing only the SFA (275.0 nmol 16:0, 18.6 
nmol 14:0, and 45.4 nmol of 18:0), MUFA (23.7 nmol 16:1, and 241.8 nmol 18:1), and 
PUFA (70.0 nmol 18:2, 0.9 nmol 20:4, and 0.4 nmol 22:6), were also prepared. To make 1 
ml of tissue culture media with each FFA mixture, the fatty acid/DMSO mixture or 10 µl 
DMSO (as vehicle control) was added at a rate of 1 µl/min to 990 µl RPMI-1640 containing 
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0.2% w/v FAF-BSA, 1% v/v A/A, 100 nM PMA, and 25 µg/ml THL while continuously 
vortexing. The media containing FFA were immediately incubated with THP-1 
macrophages. After 18 hours of incubation, the RNA was isolated using TRIzol® LS 
reagent (ThermoFisher Scientific) and the samples were stored at -80°C until use. 
2.7 RNA Isolation, Genomic DNA Removal and RNA Clean-up 
RNA was isolated from the samples stored with 1 mL of TRIzol® (see section 2.5.3 
and 2.6) as previously described (150). The samples with TRIzol® were mixed thoroughly 
with 200 μL of chloroform, then they were centrifuged at 12,000 rpm in a Legend Micro 
21 R centrifuge (ThermoFisher Scientific) for 15 minutes at 4˚C. The centrifugation yields 
three phases: an upper aqueous phase containing RNA, an interphase containing DNA, and 
a lower organic phase containing protein. The upper aqueous phase was collected and 
added to 500 μL of isopropanol in a 1.5 mL microfuge tube, then it was incubated at room 
temperature for 10-15 minutes. After incubation, the tube was centrifuged at 12,000 rpm 
in Legend Micro 21 R centrifuge (ThermoFisher Scientific) for 10 minutes at 4˚C. The 
supernatant was discarded and 1 mL of 75% ethanol was added to each tube containing 
RNA pellets to remove any impurities. The tubes containing RNA samples were then 
centrifuged at 8,800 rpm for 5 minutes at 4˚C. After centrifugation, the supernatant was 
discarded. The ethanol was evaporated completely, then 20 μL of nuclease-free water was 
added to the RNA pellet and the tube was tapped gently to dissolve and mix the RNA. The 
concentration of RNA was measured using a NanoDrop 2000 spectrophotometer 
(ThermoFisher Scientific). To remove trace genomic DNA contamination, the isolated 
RNA was treated with the TURBO® DNA-free DNAse kit (Invitrogen), as per the 
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manufacturer’s instructions. The concentration of the RNA was measured again using a 
NanoDrop 2000 spectrophotometer and the quality of RNA, both before and after DNase 
treatment, was assessed using a 1% agarose gel. The RNA was further cleaned using 
RNeasy® Mini kit (#74104, Qiagen, Toronto, ON, Canada), according to the 
manufacturer’s instructions. The quality of cleaned RNA was checked again using a 1% 
agarose gel and stored at -80˚C until further use. 
2.8 Microarray and Quantitative PCR 
2.8.1 Microarray analysis 
 The RNA isolated from macrophages incubated with either LPL hydrolysis 
products or non-hydrolysis products from three independent experiments were shipped to 
The Centre for Applied Genomics (Toronto, ON, Canada) to obtain raw data from analyses 
using the Human gene 2.0 ST GeneChip (Affymetrix, Santa Clara, CA, USA). For each 
sample, the RNA integrity was assessed at The Centre for Applied Genomics using an 
Agilent Bioanalyzer 2100; RNA integrity numbers (RIN) for all the samples were above 
eight. 
Raw microarray data received from The Centre for Applied Genomics were 
processed using Bioconductor 3.1 (151) in R 3.2.0 (152). Data were normalized with the 
RMA algorithm (153) using the Oligo package (154). Once the data were pre-processed, 
the differentially expressed genes were obtained using LIMMA (155). The model matrix 
was designed for data obtained from LPL hydrolysis product and non-hydrolysis product 
treated macrophages. The function eBayes was used to rank the differentially expressed 
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genes. Further, a top list of differentially expressed genes was obtained using the function 
topTable by adjusting the P value for false discovery rate (FDR), a multiple testing 
correction method that controls false discoveries. (Detailed line commands are provided in 
Appendix I methods).  
Lastly, gene annotation was performed using biomaRT (156,157) and confirmed 
by using NetAffxTM Affymetrix Analysis Center (Affymetrix), that provides the official 
gene symbol for each Affymetrix probe ID (158).  
 Next, the functional interaction between the genes was visualized and gene 
ontology (GO) analyses were performed using geneMANIA database (159). GeneMANIA 
database provides the function of different gene sets and performs enrichment analysis to 
determine what were the biological processes that were significantly enriched. The list of 
genes (query genes) that were differentially regulated (at FDR ≤ 0.03) were uploaded onto 
the website in order to obtain GO biological functions associated with query genes. Finally, 
enriched biological processes (at FDR < 0.05) and their associated genes were chosen, and 
select genes associated with different biological processes were validated using real-time 
PCR. 
The processed microarray data were submitted to Gene Expression Omnibus, 
according to the minimum information about microarray experiments regulations (160). 
The GEO accession number associated with our data is GSE84791. 
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2.8.2 Quantitative PCR analysis 
2.8.2.1 cDNA synthesis 
To synthesize cDNA, 500 ng of RNA samples (see section 2.5.3 and 2.6) were 
added to nuclease-free H2O (4.5 µL) in PCR tubes and placed on ice. Two different master 
mixes were prepared in 1.5 mL Eppendorf tubes, where master mix 1 contains 1 µL of 
random primers (3 µg/µL) (#48190-011, ThermoFisher Scientific) and 0.5 µL of 
deoxyribonucleotide triphosphates (10 mM) (#R0191, ThermoFisher Scientific) and 
master mix 2 contains 2 µL of 5X First-Strand Buffer (#Y02321, ThermoFisher Scientific), 
1 µL of 0.1 M dithiothreitol and 0.5 µL of 40 U/µL RNaseOutTM (#10777-019, 
ThermoFisher Scientific). The master mixes were freshly prepared for each set of samples 
that were assessed at any given time. A total of 1.5 µL of master mix 1 was added to each 
tube containing RNA samples and incubated for 5 minutes at 65˚C in an Eppendorf PCR 
machine (Eppendorf, Mississauga, ON, Canada). After 5 minutes, 3.5 µL of master mix 2 
was added to each tube and further incubated for 2 minutes at 37˚C. Lastly, 0.5 µL of 200 
U/µL M-MLV reverse transcriptase (#28025013, ThermoFisher Scientific) was added to 
each tube and mixed thoroughly. The RNA sample mixture was then incubated at the 
following conditions: 25˚C for 10 minutes, 37˚C for 50 minutes, 72˚C for 10 minutes, and 
4˚C for infinity (optional). The cDNA samples (at a concentration of 500 ng in 10 µL 
reaction volume) were further diluted to 5 ng/µL and stored at -20°C until use.  
2.8.2.2 Quantitative PCR analysis 
The relative gene expression of select genes was measured in THP-1 macrophages 
incubated with LPL hydrolysis products (biological replicates, n=3), FFA mixture 
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(biological replicates, n=3), and distinct FFA classes (biological replicates, n=3). Gene 
expression was quantified using iQ SYBR Green Supermix (Bio-Rad) or SsoAdvanced 
SYBR Green Supermix (Bio-Rad), according to manufacturer’s instructions. Primers were 
designed and used to quantify the genes encoding β-actin, small nucleolar RNA (snoRNA) 
56, snoRNA 75, dyskerin 1 variant 3, proliferating cell nuclear antigen (PCNA), ATF3, 
interferon-induced transmembrane protein 1 (IFITM1), CD36, and perilipin 2 (Integrated 
DNA Technologies, Coralville, IA, USA) (Table 1) in a CFX96TM Real-Time PCR system 
(Bio-Rad). Real-time PCR cycle conditions were 1 cycle of 95°C for 3 minutes, and 40 
cycles of 95°C for 15 seconds, 59.5°C for 15 seconds, and 72°C for 20 seconds.   
Amplification efficiencies of select genes (Table S1) were calculated as previously 
described by Pfaffl et al. (161). Briefly, cDNA synthesized from LPL hydrolysis product- 
and non-hydrolysis product-treated THP-1 macrophages were pooled together. Different 
amounts of pooled cDNA (50 ng, 10 ng, 2 ng, 0.4 ng, 0.08 ng, and 0.016 ng) were added 
to 1 µL of 500 nM select gene primers (both forward and reverse primers), 10 µL of iQ 
SYBR Green Supermix, and an appropriate volume of nuclease-free H2O (Thermo Fisher 
Scientific) to adjust the final volume to 20 µL. Threshold cycle (Ct) values were obtained 
by performing qPCR following the above cycle conditions.  Log cDNA inputs were plotted 
against Ct values obtained for each select genes. The slope obtained from the graph was 
used in the following equation to obtain amplification efficiency: 
                                  E= 10[-1/slope]                                                                                                 (equation 2)   
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Table 1: List of primer sequences for select genes 
 
The primer sequences for target genes and a reference genes are listed above. ACTB 
encodes β-actin. ADPF, an alternate symbol for PLIN2, encodes perilipin 2. Melting curve 
analysis of forward and reverse primers of each respective gene showed that primers 
amplified only one product (data not shown). 
  
Gene Forward Primer Reverse Primer 
ACTB 
NC_000007.13 
5’‐ ACC TTC TAC AAT GAG CTG CG‐ 3’ 
Template: 349 ……..………………..…368 
5’‐ CCT GGA TAG CAA CGT ACA TGG ‐3’ 
Template: 537…………………….……...517 
ATF3 
XM_011509579.1 
5’- AGT GAG TGC TTC TGC CAT CG- 3’ 
Template: 228………………..…….…..247 
5’- GCA GAG GTG CTT GTT CTG GA- 3’ 
Template: 354…………….……………335 
ADRP 
XM_017014259.1 
5’- TAA CAA CAC GCC CCT CAA CT-3’ 
Template: 1301………..……………..1320 
5’- GAG GAC AGG GCC ATT AGC AT- 3’ 
Template: 1439………………………..1420 
CD36 
XM_011516707.1 
5’-TTG ATG TGC AAA ATC CAC AGG-3’ 
Template: 323…………………….…….343 
5’-TGT GTT GTC CTC AGC GTC CT- 3’ 
Template: 453………...…………...….434 
PCNA 
NM_002592.2 
5’- GGC GTG AAC CTC ACC AGT AT- 3’ 
Template: 444…………………….….....463 
5’- TTC TCC TGG TTT GGT GCT TC- 3’ 
Template: 568………………………....549 
IFITM1 
NM_003641.3 
5’- GAC AGG AAG ATG GTT GGC GA- 3’ 
Template: 373……………………..….…392 
5’- GGT AGA CTG TCA CAG AGC CG- 3’ 
Template: 517……………………….….498 
SNORA75 
NR_002921.1 
5’- TCT TCT CAT TGA GCT CCT TTC T- 3’ 
Template: 2………..…………...………..…23 
5’-AAT GTC TCA CAA TAC AGC TAA A- 3’ 
Template: 136………………………......….115 
SNORA56 
NM_001288747.1 
5’- TTC TAG TCT GGC TCG TGG GA-3’ 
Template: 1794………………………1813 
5’- TGG CAA GTC TAA AGC CAC CA -3’ 
Template: 1897…….……………….…1878 
DKC1-v3 
NM_001288747.1 
5’- GTA GAG ACG GCA CAC TTG CT- 3’ 
Template: 1515………..………..……..1534 
5’- ACA ACC TCC ATG CTC ACC TG -3’ 
Template: 1650……………………….1631 
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where E denotes amplification efficiency in equation 2. All qPCR reactions were 
performed in duplicate to measure efficiency. Melting curves (not shown) were assessed 
to ensure only one product was amplified. Next, the gene expression analysis for select 
genes was performed by calculating the relative expression ratio as previously described 
(161). Briefly, 25 µL of reaction mixture was prepared by adding 5 µL of 5 ng/µL cDNA 
or non-template control to 1.25 µL of 500 nM select gene primers (both forward and 
reverse), 12.5 µL of IQ SYBR Green Supermix, and 5 µL of nuclease-free H2O. All 
reactions were performed in triplicate and target genes were normalized to β-actin 
(reference gene). 
The relative expression ratio was measured using the following mathematical 
model: 
    (Etarget) ΔCPtarget (control-sample)  
                                                                 (Eref) ΔCPref (control-sample)                           (equation 3)    
where Etarget and Eref represents the amplification efficiency of select target gene and β-
actin, respectively. ΔCPtarget and ΔCPref refers to the difference in Ct values between the 
control versus the treated target genes or the reference gene, respectively. Data are 
presented as mean percentage relative to control treatments.  
2.9 Statistical Analysis 
Unless otherwise stated, an unpaired student’s t-test was performed to determine 
statistical significance and the standard deviation (SD).  
Ratio = 
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Chapter 3: Results 
3.1 Microarray Analyses of THP-1 Macrophages in Response to Lipoprotein 
Hydrolysis Products 
The immunoblot analyses of heparinized media from LPL expressing cells showed 
that the heparinized media contained full length LPL protein, as well as significant lipase 
activity versus heparinized media from mock-transfected cells (Figure. 4). We incubated 
3.5 mM (by PL) of total lipoproteins, isolated from normolipidemic subjects, with 
heparinized media from HEK-293 cells expressing human LPL. As expected, after a               
4 hours incubation at 37°C, the amount of FFA liberated by LPL was significantly higher 
versus the amount of FFA observed following incubation with heparinized media from 
control cells (Figure. 5). The lipoprotein hydrolysis products generated by LPL were 
diluted to a FFA concentration of 0.68 mM; the diluted lipoprotein hydrolysis products 
were incubated with THP-1 macrophages for 18 hours, and RNA was isolated for 
microarray analyses. The total lipoproteins treated with control media were comparably 
diluted to yield a FFA concentration of 0.03 mM; these control samples were also incubated 
with THP-1 macrophages for 18 hours. Both treatments did not affect cell viability, based 
on Trypan Blue exclusion assays (Figure. 6). 
Although the RNA integrity number was consistently above eight from all of the 
samples, the integrity of the THP-1 RNA that was isolated following incubations with total 
lipoprotein hydrolysis products was consistently lower versus control cells (8.45±0.26 
versus 9.45±0.058, respectively – P<0.001).   
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Figure 4: LPL protein expression and catalytic activity 
HEK-293 cells were transfected either with pcDNA3 containing the human LPL cDNA or 
no pcDNA3 (Mock). Heparinized media and cell lysates were collected. (A) Immunoblot 
analysis for LPL of cell lysates from transfected cells and heparinized media from the 
transfected cells. (B) Catalytic activity of heparinized media from non-transfected (Mock) 
or transfected cells toward a resorufin ester substrate. Data are presented as the mean ± SD 
from triplicate experiments. 
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Figure 5: Hydrolysis of total lipoproteins by heparinized media 
HEK-293 cells were transfected either with pcDNA3 containing the human LPL cDNA or 
no pcDNA3 (Mock). Heparinized media from these cells, collected as described under 
section 2.2.2, were incubated with total lipoproteins (Lipo; d < 1.21 g/mL, 3.5 mM by PL) 
for 4 h, as described under section 2.5.1. The FFA generated were quantified and data 
represent the mean ± SD from triplicate experiments. 
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Figure 6: The effect of LPL hydrolysis products on THP-1 macrophage cell viability 
THP-1 macrophages were incubated for 18 hours with total lipoprotein hydrolysis products 
that were generated by LPL or control heparinized media. After 18 hours, cells were 
incubated with Trypan Blue and counted, as described under section 2.5.3.1. Data are 
presented as a percent of control ± SD from triplicate experiments. 
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 Our RNA integrity data showed that the levels of both 28S and 18S ribosomal RNA was 
reduced in response to total lipoprotein hydrolysis products, concomitantly with an unusual 
appearance of small RNA bands (Figure 7). 
Microarray analyses of transcripts from THP-1 macrophages incubated in the 
absence or presence of total lipoprotein hydrolysis products generated by LPL revealed 
that 316 transcripts were differentially regulated at a FDR ≤ 0.03. Out of the 316 
differentially regulated transcripts, 183 transcripts (with 145 unique genes and 16 
uncharacterized transcripts) were upregulated in response to lipoprotein hydrolysis 
products, while 133 transcripts (with 118 unique genes and 6 uncharacterized transcripts) 
were downregulated (Appendix II, Table S2; and Appendix II, Table S3). Of note, 63 of 
the upregulated transcripts were snoRNAs. Fourteen of the 63 snoRNAs we identified 
exhibited a fold change of four or greater (Table 2). 
A total of 157 differentially regulated transcripts encode functional proteins. Using 
the GeneMANIA database, an enrichment analysis of the gene ontologies associated with 
these transcripts showed that eight GO biological processes were significantly influenced 
by total lipoprotein hydrolysis products generated by LPL (p<0.05). These processes 
include DNA replication (16 transcripts, GO:0006260), chromosome segregation (10 
transcripts, GO:0007059), unfolded protein response (8 transcripts, GO:0006986), ER 
stress response (7 transcripts, GO:0034976), type I interferon signaling response (8 
transcripts, GO:0071357), sterol metabolism (6 transcripts, GO:0016125), cellular metal 
ion homeostasis (11 transcripts, GO:0006875), and regulation of nuclease activity (9  
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Figure 7: The effect of total lipoprotein hydrolysis products generated by LPL on 
THP-1 RNA integrity 
Total lipoproteins (d < 1.21 g/ml, 3.5 mM by PL) were incubated for 4 h at 37°C with either 
heparinized media from non-transfected HEK-293 cells, or heparinized media from HEK-
293 cells expressing human LPL. THP-1 cells were incubated for 18 hours with the 
hydrolysis products (Control, 0.03 mM; LPL, 0.68 mM by FFA), and RNA were isolated. 
RNA were separated in an Affymetrix Bioanalyzer. All samples had an RNA integrity 
number value above eight. Data are representative of four biological replicates. 
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Figure 7 
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Table 2: SnoRNA molecules identified by microarray analyses with at least a four-fold increase of expression in THP-1 
macrophages in response to total lipoprotein hydrolysis products liberated by LPL 
Gene Description Host Gene* Target RNA* Fold Change 
SNORA60 small nucleolar RNA, H/ACA box 60 SNHG11 18S rRNA U1004 12.01 
SNORA75 small nucleolar RNA, H/ACA box 75 NCL 18S rRNA U93 6.59 
SNORA14B small nucleolar RNA, H/ACA box 14B TOMM20 18S rRNA U966 6.45 
SNORA80E small nucleolar RNA, H/ACA box 80E KIAA0907 18S rRNA U572 and U109 6.30 
SNORA76C small nucleolar RNA, H/ACA box 76C SNHG25 18S rRNA U34 and U105 5.19 
SNORA11 small nucleolar RNA, H/ACA box 11 MAGED2 Nil 5.11 
SNORA2A small nucleolar RNA, H/ACA box 2A FLJ20436 28S rRNA U4263 and U4282 4.84 
SNORA42 small nucleolar RNA SNORA42/SNORA80 family KIAA0907 18S rRNA U572 and 18S rRNA U109 4.77 
SNORA33 small nucleolar RNA, H/ACA box 33 RPS12 28S rRNA U4966 4.69 
SCARNA8 small Cajal body-specific RNA 8 FAM29A U2 spliceosome 4.46 
SNORA56 small nucleolar RNA, H/ACA box 56 DKC1 28S rRNA U1664 4.23 
SCARNA4 small Cajal body-specific RNA 4 KIAA0907 U2 snRNA U41 and U39 4.12 
SNORA71B small nucleolar RNA, H/ACA box 71B SNHG17 18S rRNA U406 4.02 
SNORD92 small nucleolar RNA, C/D box 92 D26488 28S rRNA A3846 4.00 
* Information on host genes and target RNA obtained from the snoRNA-LBME-db database (162) 
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transcripts, GO:0032069) (Table 3). The GO biological processes of DNA replication and 
chromosome segregation are sub-categories of the cell cycle. Interestingly, with the 
exception of DKC1 variant 3 (DKC1-v3), the expression of all genes identified from these 
sub-categories were downregulated. The expression of all genes that were identified within 
the GO biological process of type I interferon signaling response were also downregulated. 
On the other hand, the expression of all genes identified within the GO biological process 
of unfolded protein response was upregulated. Description on enrichment analysis (Table 
S4) and fold change of genes associated with each selected processes (Table S5) are 
provided in Appendix II. 
We identified genes within the GO biological process of sterol metabolism that 
were either upregulated or downregulated in response to total lipoprotein hydrolysis 
products. However, we did not identify other GO biological processes associated with lipid 
metabolism. This is likely due to the lack of over-representation of genes associated with 
lipid metabolism following multiple corrections. However, the manual analysis of the top 
differentially expressed genes (at FDR ≤ 0.03) showed that the treatment of THP-1 
macrophages with total lipoprotein hydrolysis products generated by LPL altered the 
expression of FABP4 (5.4-fold increase), ACAT2 (2.0-fold decrease), LDLR (1.7-fold 
decrease), FASN (2.0-fold decrease), FADS1 (1.7-fold decrease), FADS2 (2.1-fold 
decrease), CD36 (2.9-fold increase), PLIN2 (2.9-fold increase), and CPT1A (3-fold 
increase) (Appendix II, Table S2; and Appendix II, Table S3). 
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Table 3: List of significantly over-represented GO Biological processes and the genes identified within these processes by 
microarray analyses 
 
GO Biological Process 
Number of Genes 
Identified from 
Microarray 
Analyses 
Genes in 
Genome 
List of Genes Identified from Microarray Analyses Enriched 
P Value 
DNA replication (GO: 0006260) 16 222 DKC1-v3, CDC25A, MCM7, POLQ, CHEK1, PCNA, MCM4, E2F8, MCM3, 
MCM6, RAD51, MCM8, DSCC1, ESCO2, TYMS, TOP2A 
7.3×10-7 
Chromosome segregation (GO: 
0007059) 
10 128 CENPE, NUSAP1, SKA3, DSCC1, BUB1, NCAPH, CASC5, TOP2A, NCAPG, 
SKA1 
3.0×10-4 
Response to unfolded protein (GO: 
0006986) 
8 106 HSPA1A, ATF3, HSP90B1, HSPA5, KDELR3, DNAJB1, ACADVL, HYOU1 3.1×10-3 
Response to ER stress (GO: 0034976) 7 113 ATF3, HSP90B1, HSPA5, KDELR3, ACADVL, HYOU1, CHAC1 2.2×10-2 
Response to type 1 interferon (GO: 
0071357) 
8 74 IFI27, IFIT1, OAS1, MX2, OAS3, XAF1, OAS2, IFITM1 3.6×10-4 
Sterol metabolic process (GO: 
0016125) 
6 80 CYP27A1, ACADVL, FDPS, HMGCS1, DHCR24, DHCR7 2.4×10-2 
Cellular metal ion homeostasis (GO: 
0006875) 
11 264 ATP6V0D2, ABCG2, HSP90B1, CD52, TPT1, HMOX1, C3AR1, P2RX7, 
PTK2B, CCL1, CXCL10 
9.9×10-3 
Regulation of nuclease activity (GO: 
0032069) 
9 73 ATF3, HSP90B1, HSPA5, KDELR3, ACADVL, HYOU1, PCNA, OAS1, OAS3 6.8×10-5 
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3.2 Validation of Expression for Select Genes by Real-Time PCR 
We treated THP-1 macrophages for 18 hours with total lipoprotein hydrolysis 
products that were generated by LPL, as above, for the purpose of validating the expression 
of select genes by real-time PCR that we identified in the microarray analyses (Table 4). 
We chose to validate the expression of two snoRNA genes that were increased in response 
to lipoprotein hydrolysis products generated by LPL: SNORA56 and SNORA75. We also 
chose to validate DKC1-v3 and PCNA (both from the GO biological process of cell cycle), 
ATF3 (from the GO biological process of stress response), and IFITM1 (from the GO 
biological process of type I interferon signaling); genes from each of these processes were 
chosen because these GO biological processes appear to play a role in atherosclerosis (163-
165). Lastly, we also assessed the expression of the lipid metabolism genes CD36 and 
PLIN2 – both of which were found to be significantly upregulated (FDR ≤ 0.03) in response 
to total lipoprotein hydrolysis products. Overall, with the exception of SNORA75, which 
showed no difference between the absence or presence of hydrolysis products (Figure 8A), 
the changes of expression for the remaining seven genes were significant and similar to the 
microarray data (Figure 8B-H). 
3.3 Select Gene Expression in Response to FFA 
We previously reported the molar amounts of FFA that were liberated by LPL from 
total lipoproteins; based on these data, we have previously prepared and tested a mixture 
of purified FFA (that represents the FFA component of total lipoprotein hydrolysis 
products) on its influence on cell signaling nodes and cholesterol efflux (77,137). We  
62 
 
Table 4: Genes from microarray analyses that were selected for further study 
Affymetrix 
Transcript 
ID 
Gene 
Symbol Description 
Fold Change in 
Microarray 
Microarray P 
Value 
(at FDR ≤ 0.03) 
16909520 SNORA75 Small nucleolar RNA 75 6.6 0.006 
17119802 SNORA56 Small nucleolar RNA 56 4.2 0.006 
17119802 DKC1-v3 Dyskerin (variant 3) 4.2 0.006 
16720085 IFITM1 Interferon-induced transmembrane protein 1 4 0.005 
17047795 CD36 Cluster of differentiation 36 2.9 0.006 
16916958 PCNA Proliferating cell nuclear antigen 1.99 0.02 
16677278 ATF3 Activating transcription factor 3 2.9 0.007 
17092712 PLIN2 Perilipin 2 2.9 0.006 
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Figure 8: Validation of expression of select genes within THP-1 macrophages 
incubated with total lipoprotein hydrolysis products generated by LPL 
Total lipoproteins (d < 1.21 g/ml, 3.5 mM by phospholipid) were incubated for 4 h at 37°C 
with either heparinized media from non-transfected HEK-293 cells, or heparinized media 
from HEK-293 cells expressing human LPL. THP-1 cells were incubated for 18 hours with 
the hydrolysis products (Control, 0.03 mM; LPL, 0.68 mM by FFA), and RNA were 
isolated for the quantitative real-time PCR analyses of (A) SNORA75; (B) SNORA56; (C) 
DKC1-v3; (D) IFITM1; (E) CD36; (F) PCNA; (G) ATF3; and (H) PLIN2. All data were 
normalized to the expression of β-actin, and data are presented as a percent of control ± SD 
from three biological replicates. 
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Figure 8 (cont.) 
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Figure 8 (cont.) 
(E) 
Control LPL
0
200
400
600
800 P=0.0005
Control
LPL
C
D
36
 /
β
-a
ct
in
 m
R
N
A
(%
 o
f c
on
tr
ol
)
 
 
 
(F) 
Control LPL
0
50
100
150
P=0.008
LPL
Control
PC
N
A
 /
β
-a
ct
in
 m
R
N
A
(%
 o
f c
on
tr
ol
)
 
  
67 
 
Figure 8 (cont.) 
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prepared a 0.68 mM FFA mixture, to match the concentration of FFA within our hydrolysis 
products, and we incubated THP-1 macrophages with the mixture for 18 hours in an 
attempt to determine the role of the FFA component of hydrolysis products on the 
expression of our seven validated genes. Real-time PCR analyses showed that no 
significant changes were observed for the expression of SNORA56 (Figure 9A), DKC1-v3 
(Figure 10A), IFITM1 (Figure 11A), and CD36 (Figure 12A). However, the FFA mixture 
significantly reduced the gene expression of PCNA by 20% (Figure 13A), ATF3 by 37% 
(Figure 14A), and PLIN2 by 25% (Figure 15A). 
Lastly, to further assess how the FFA component influences the expression of our 
seven validated genes, we prepared and tested FFA mixtures that only contained the SFA, 
MUFA, or PUFA components of the total lipoprotein hydrolysis products. These mixtures 
were incubated with THP-1 macrophages for 18 hours, and gene expression levels were 
quantified by real-time PCR. The expression of SNORA56 significantly decreased by 36% 
in response to SFA (Figure 9B), but it did not change in response to MUFA (Figure 9C) or 
PUFA (Figure 9D). Similarly, the expression of DKC1-v3 significantly decreased by 31% 
in response to SFA (Figure 10B), but it did not change in response to MUFA (Figure 10C) 
or PUFA (Figure 10D). Similar to what was observed for the total FFA mixture, the gene 
expression for IFITM1 was unaffected by the SFA, MUFA, or PUFA mixtures (Figure 
11B-D). Our data show that the gene expression of CD36 was significantly reduced by 
34% in the presence of MUFA (Figure 12C), however, the SFA and PUFA mixtures had 
no significant effect on expression (Figure 12B and 12D, respectively). While the total  
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Figure 9: The influence of the FFA component of total hydrolysis products on 
SNORA56 expression in THP-1 macrophages 
THP-1 macrophages were incubated for 18 hours with a vehicle control (DMSO) or with 
(A) a 0.68 mM total FFA mixture representing the FFA component of total lipoprotein 
hydrolysis products liberated by LPL; (B) the saturated fatty acid (SFA) component of the 
total FFA mixture; (C) the monounsaturated fatty acid (MUFA) component of the total 
FFA mixture; and (D) the polyunsaturated fatty acid (PUFA) component of the total FFA 
mixture. RNA were isolated following incubations and used to quantify SNORA56 by 
quantitative real-time PCR. All data were normalized to the expression of β-actin, and data 
are presented as a percent of control ± SD from three biological replicates.  
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Figure 9 (cont.) 
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Figure 10: The influence of the FFA component of total hydrolysis products on 
DKC1-v3 expression in THP-1 macrophages 
THP-1 macrophages were incubated for 18 hours with a vehicle control (DMSO) or with 
(A) a 0.68 mM total FFA mixture representing the FFA component of total lipoprotein 
hydrolysis products liberated by LPL; (B) the saturated fatty acid (SFA) component of the 
total FFA mixture; (C) the monounsaturated fatty acid (MUFA) component of the total 
FFA mixture; and (D) the polyunsaturated fatty acid (PUFA) component of the total FFA 
mixture. RNA were isolated following incubations and used to quantify DKC1-v3 by 
quantitative real-time PCR. All data were normalized to the expression of β-actin, and data 
are presented as a percent of control ± SD from three biological replicates.  
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Figure 10 (cont.) 
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Figure 11: The influence of the FFA component of total hydrolysis products on 
IFITM1 expression in THP-1 macrophages 
THP-1 macrophages were incubated for 18 hours with a vehicle control (DMSO) or with 
(A) a 0.68 mM total FFA mixture representing the FFA component of total lipoprotein 
hydrolysis products liberated by LPL; (B) the saturated fatty acid (SFA) component of the 
total FFA mixture; (C) the monounsaturated fatty acid (MUFA) component of the total 
FFA mixture; and (D) the polyunsaturated fatty acid (PUFA) component of the total FFA 
mixture. RNA were isolated following incubations and used to quantify IFITM1 by 
quantitative real-time PCR. All data were normalized to the expression of β-actin, and data 
are presented as a percent of control ± SD from three biological replicates.  
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Figure 11 (cont.) 
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Figure 12: The influence of the FFA component of total hydrolysis products on 
CD36 expression in THP-1 macrophages 
THP-1 macrophages were incubated for 18 hours with a vehicle control (DMSO) or with 
(A) a 0.68 mM total FFA mixture representing the FFA component of total lipoprotein 
hydrolysis products liberated by LPL; (B) the saturated fatty acid (SFA) component of the 
total FFA mixture; (C) the monounsaturated fatty acid (MUFA) component of the total 
FFA mixture; and (D) the polyunsaturated fatty acid (PUFA) component of the total FFA 
mixture. RNA were isolated following incubations and used to quantify CD36 by 
quantitative real-time PCR. All data were normalized to the expression of β-actin, and data 
are presented as a percent of control ± SD from three biological replicates.  
  
79 
 
Figure 12 
(A) 
DMSO FFA mixture
0
50
100
150 P=0.48
DMSO
FFA mixture
C
D
36
 /
β
-a
ct
in
 m
R
N
A
(%
 o
f c
on
tr
ol
)
 
 
 
(B) 
DMSO SFA
0
50
100
150
P=0.06
DMSO
SFA
C
D
36
 /
β
-a
ct
in
 m
R
N
A
(%
 o
f c
on
tr
ol
)
 
  
80 
 
Figure 12 (cont.) 
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Figure 13: The influence of the FFA component of total hydrolysis products on PCNA 
expression in THP-1 macrophages 
THP-1 macrophages were incubated for 18 hours with a vehicle control (DMSO) or with 
(A) a 0.68 mM total FFA mixture representing the FFA component of total lipoprotein 
hydrolysis products liberated by LPL; (B) the saturated fatty acid (SFA) component of the 
total FFA mixture; (C) the monounsaturated fatty acid (MUFA) component of the total 
FFA mixture; and (D) the polyunsaturated fatty acid (PUFA) component of the total FFA 
mixture. RNA were isolated following incubations and used to quantify PCNA by 
quantitative real-time PCR. All data were normalized to the expression of β-actin, and data 
are presented as a percent of control ± SD from three biological replicates.  
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Figure 13 (cont.) 
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Figure 14: The influence of the FFA component of total hydrolysis products on ATF3 
expression in THP-1 macrophages 
THP-1 macrophages were incubated for 18 hours with a vehicle control (DMSO) or with 
(A) a 0.68 mM total FFA mixture representing the FFA component of total lipoprotein 
hydrolysis products liberated by LPL; (B) the saturated fatty acid (SFA) component of the 
total FFA mixture; (C) the monounsaturated fatty acid (MUFA) component of the total 
FFA mixture; and (D) the polyunsaturated fatty acid (PUFA) component of the total FFA 
mixture. RNA were isolated following incubations and used to quantify ATF3 by 
quantitative real-time PCR. All data were normalized to the expression of β-actin, and data 
are presented as a percent of control ± SD from three biological replicates.  
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Figure 14 (cont.) 
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Figure 15: The influence of the FFA component of total hydrolysis products on PLIN2 
expression in THP-1 macrophages 
THP-1 macrophages were incubated for 18 hours with a vehicle control (DMSO) or with 
(A) a 0.68 mM total FFA mixture representing the FFA component of total lipoprotein 
hydrolysis products liberated by LPL; (B) the saturated fatty acid (SFA) component of the 
total FFA mixture; (C) the monounsaturated fatty acid (MUFA) component of the total 
FFA mixture; and (D) the polyunsaturated fatty acid (PUFA) component of the total FFA 
mixture. RNA were isolated following incubations and used to quantify PLIN2 by 
quantitative real-time PCR. All data were normalized to the expression of β-actin, and data 
are presented as a percent of control ± SD from three biological replicates.  
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Figure 15 (cont.) 
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FFA mixture reduced the expression of PCNA, each class of FFA did not affect its 
expression (Figure 13). ATF3 was the only gene from our validated genes that responded 
to each class of FFA: SFA treatment increased expression by 69%, MUFA treatment 
reduced expression by 87%, and PUFA treatment reduced expression by 41% (Figure 14B-
D). The expression of PLIN2 significantly decreased by 30% in response to SFA (Figure 
14B) and significantly decreased by 62% in response to MUFA (Figure 15C), but no 
differences were observed in response to PUFA (Figure 15D). 
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Chapter 4: Discussion 
4.1 Modulation of snoRNA Expression by FFA Components within LPL Hydrolysis 
Products may Affect Ribosome Biogenesis in Human Macrophages 
In this study, we performed a transcriptomic analysis to assess changes in gene 
expression by THP-1 macrophages when exposed to the hydrolysis products that were 
liberated from total lipoproteins by LPL. The most interesting result, though the most 
difficult to decipher, was the increased expression of several snoRNA molecules. These 
non-coding small RNA molecules play a central role in guiding chemical modifications, 
particularly in ribosomal RNA, transfer RNA, and small nuclear RNA. The snoRNAs are 
classified as either H/ACA box-type or C/D box-type, based on their sequence recognition 
motifs; H/ACA box-type snoRNAs guide pseudouridylation and C/D box-type snoRNAs 
guide methylation (166). The integrity of the THP-1 RNA that was isolated following 
incubations with total lipoprotein hydrolysis products was consistently lower versus 
control cells. Liu et al. (167) previously reported that mistargeted chemical modifications 
can also induce ribosomal RNA degradation and impair cell growth. The roles and targets 
of most snoRNAs are not known, although recent studies have established an emerging 
role of snoRNAs in other cellular functions, such as roles in unfolded protein responses 
(168) and regulating cholesterol transport between the plasma membrane and ER (169). It 
is possible that snoRNAs play a direct role in the differentiation of macrophages into foam 
cells, possibly by modifying ribosomal RNA and leading to an arrest of cell growth. While 
this is an attractive hypothesis, a significant amount of work is needed to decipher which 
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snoRNA, or combination of snoRNAs, may be involved. In the present study, the 
expression of two H/ACA box-type snoRNAs, SNORA56 and SNORA75 were evaluated, 
within THP-1 macrophages in response to total lipoprotein hydrolysis products, as well as 
in response to the FFA component of hydrolysis products. SNORA75 is encoded within the 
12th intron of NCL, the gene encoding nucleolin. SNORA75 has been reported to guide 
pseudouridylation in 18S ribosomal RNA (170,171). Our quantitative real-time PCR data 
failed to validate any change in SNORA75 expression, and together with a lack of change 
to the expression of NCL (based on microarray data) within THP-1 macrophages in 
response to total lipoprotein hydrolysis products. SNORA56 is encoded within the 12th 
intron of DKC1, and it has been reported to guide pseudouridylation in 28S ribosomal RNA 
(171,172). Intriguingly, a specific variant of DKC1, variant 3, has been shown to retain the 
sequence of SNORA56 in its mature mRNA (173), and thus in addition to SNORA56, 
DKC1-v3 expression was also evaluated; its function is not well understood. The total 
lipoprotein hydrolysis products generated by LPL increased the expression of DKC1-v3 
and SNORA56, but the total FFA component had no influence on their expression. This 
suggests that other components of LPL hydrolysis products play a role in regulating their 
expression. However, the SFA component of the total FFA did alter the expression of 
selected snoRNA genes. Michel et al. (174) had previously shown that SFA can induce the 
expression of three C/D box snoRNAs that are encoded in the RPL13A gene in Chinese 
hamster ovary cells, and a knockdown of these snoRNAs using antisense oligonucleotides 
protected cells against palmitate-induced cell lipotoxicity. While the functions of 
snoRNA75 and DKC1-v3/snoRNA56 remain to be clearly elucidated, it is possible that 
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total lipoprotein hydrolysis products from dyslipidemic subjects with high levels of plasma 
SFA would alter their function by altering expression. SFAs are well known to induce 
lipotoxicity and pro-inflammatory responses in cells. High levels of plasma SFAs could 
not only induce metabolic stress in cells, but it could also possibly affect the regulation of 
DNA binding transcription factors, that in turn will modify gene expression levels. 
However, the mechanisms by which SFAs control the activity of transcription factors 
remains to be elucidated. 
4.2 LPL Hydrolysis Products Alter Select Cell Cycling Gene in THP-1 Macrophages 
Using immunocytochemistry studies, Gordon et al. (163) reported that smooth 
muscle cell (SMC) and macrophage cell proliferation occur at low rates in the 
atherosclerotic plaques of human arteries and carotid balloon catheter injured rat arteries, 
suggesting that the cell cycling process may be altered in foam cells. In this study, 
enrichment analyses results showed that the genes associated with select cell cycle 
processes were all down-regulated except DKC1-v3, which indicates that the LPL 
hydrolysis products may hinder macrophage cell proliferation and may be triggering them 
to form foam cells. Among the differentially regulated cell cycle genes, PCNA was selected 
as this gene plays a substantial role in DNA replication and repair, and serves as a marker 
for cell proliferation across different cell cycle stages, such as G1, S, and G2 phases (175). 
In our study, we observed a reduced expression of PCNA mRNA in THP-1 macrophages 
treated with total lipoprotein hydrolysis products generated by LPL, as well as with the 
total FFA component of the hydrolysis products. Previously, Artwohl et al. (176) 
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established the effects of individual fatty acids on impairing different cell cycle stages in 
human umbilical vein endothelial cells. Their results showed that individual species of FFA 
did arrest the cell cycle of human umbilical vein endothelial cells at concentrations of up 
to 300 µM, demonstrating that distinct FFA species do affect cell proliferation; however, 
it is likely in our study that either the concentrations of FFA within our incubations with 
SFA, MUFA, or PUFA did not achieve a minimum threshold to affect PCNA expression, 
or the correct combination of these FFA, as present in the total FFA mixture, was not 
present in the SFA, MUFA, and PUFA mixtures. 
4.3 The Role of LPL Hydrolysis Products and their FFA Components in Modulating 
Select Stress Response Gene in Human Macrophages 
Previously, studies have established a correlation between ER stress in 
macrophages and atherogenesis. For instance, Zhou et al. (177) observed that unfolded 
protein response (UPR) activation occurs at both the early-lesion stage and advanced-lesion 
stage in apoE-null mice fed with chow diet. However, UPR stimulation and cholesterol 
accumulation did not correlate with macrophage apoptotic cell death in the early-lesion 
stage. A previous study showed that ER stress stimulated lipid accumulation in 
macrophages and regulated macrophage phenotype differentiation (178). The authors also 
showed that the suppression of ER stress shifted the M2 macrophage phenotype toward an 
M1 phenotype, which promoted HDL and apoA-I-mediated cholesterol efflux in 
macrophages (178). In addition, Myoishi et al. (179) studied ER stress in coronary artery 
segments from autopsied patients and atherectomy specimens from patients with unstable 
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angina pectoris; the authors reported that ER stress and apoptosis were increased in 
macrophages and SMCs found in the thin-cap of atheroma and ruptured plaques. The genes 
involved in stress responses were another biological process that was of intrigue, since all 
genes involved in this process were significantly up-regulated.  
ATF3, a transcription factor that belongs to the cyclic AMP responsive element-
binding protein family, and participates in the stress response (180) was selectively 
validated. Aung et al. (181) previously showed that LPL lipolytic products increase the 
expression of ATF3 in aortic endothelial cells. My data are in agreement with this study, 
such that ATF3 expression was increased in THP-1 macrophages in the presence of total 
lipoprotein hydrolysis products generated by LPL. It is worth noting that ATF3-null mice 
were shown to be resistant to vascular apoptosis (181), thus my data augment the in vivo 
study, by suggesting that LPL and likely its hydrolysis products are pro-atherogenic in 
nature within macrophages, in part through its influence on ATF3 expression. However, 
the attempt to dissect how FFA affects ATF3 expression revealed a complex story, such 
that the total FFA mixture, as well as the MUFA and PUFA mixtures, reduced the 
expression of ATF3, while the SFA mixture raised the levels of ATF3. Consistent with the 
latter observation, Krogmann et al. (182) and Suganami et al. (183) also reported that SFA 
treatments induce ATF3 expression in HAECs and in RAW264 macrophage cells. 
However, unsaturated fatty acids did not significantly change ATF3 expression in their 
studies, but significant reduction in ATF3 mRNA expression was noticed upon unsaturated 
fatty acid treatment in my study. This controversy emphasizes the need for further study in 
the future.  
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4.4 The Effects of LPL Hydrolysis Products and the FFA Components in Impairing 
Macrophage Immune Response  
Previous studies have shed some light on the role type I interferon signaling in 
atherosclerosis. Although the effect of type I interferon signaling in cellular antiviral 
responses is well established, the absence of type I interferon signaling in myeloid cells 
had been shown to reduce atherosclerosis in LDLR- and apoE-null mice (184). All genes 
associated with type I interferon signaling were downregulated in my study, which 
indicates that the LPL hydrolysis products may negatively affect immune function of 
macrophages. IFITM1, which showed a maximum fold-change compared to other genes in 
this process, was selected for analysis. The IFITM1 gene is regulated by type 1 interferon 
and is involved in immune response signaling (185). A recent microarray study assessing 
monocyte-derived macrophages from human subjects with systemic lupus erythematosus 
and atherosclerosis showed decreases in many signal transduction genes, including IFITM1 
(165). This study suggested that macrophage-derived foam cells likely have compromised 
immune responses (165). However, the siRNA-mediated inhibition of IFITM1 has been 
shown to inhibit cell proliferation and to increase cell death in estrogen receptor-positive 
human breast cancer cell lines (186) – two processes that occur during the differentiation 
of macrophages into foam cells, ultimately contributing to atherosclerosis development. 
My validation data confirmed a decrease in IFITM1 expression in response to total 
lipoprotein hydrolysis products generated by LPL; however, mixtures of purified FFA did 
not affect its expression. Thus, it is likely that components other than FFA within the total 
lipoprotein hydrolysis products are involved modulating the expression of IFITM1. 
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4.5 LPL Hydrolysis Products, but not their FFA Components, Induce Lipid 
Accumulation Genes in Human Macrophages 
In my study, I verified the microarray data and showed by quantitative real-time 
PCR that the expression of CD36 was increased in THP-1 macrophages treated with total 
lipoprotein hydrolysis products generated by LPL. CD36 is a well-known class B 
scavenger receptor that has been reported to uptake lipids into macrophages, but its roles 
are still not well understood, as evidenced by conflicting studies that showed its deletion 
in mouse models to either reduce atherosclerosis or have no effect (187). My data showing 
that the expression of CD36 in response to FFA adds to this controversy. Vallvé et al. (188) 
previously reported that treating THP-1 macrophages with 10 µM MUFA or PUFA 
increased the expression of CD36, whereas no changes were observed with SFA at as high 
as 100 µM. The latter observation is consistent with those in my study, however, I observed 
that only the MUFA component of total lipoprotein hydrolysis products liberated by LPL 
affected CD36 expression, though negatively. A possible explanation behind these 
differences would be differences of FFA concentration, as the total MUFA and PUFA 
concentrations used in my study, which match those observed in total lipoprotein 
hydrolysis products generated by LPL, were 335.5 µM and 1.3 µM, respectively. The total 
FFA concentrations in my study were within physiological levels that are seen within the 
bloodstream (148), and thus it is possible that my data reflect some of the in vivo 
controversies of CD36. 
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I showed that the expression of PLIN2, which encodes the lipid droplet-associated 
protein perilipin 2, is decreased in the presence of the FFA component of LPL hydrolysis 
products, as well as in the presence of its SFA and MUFA components. However, this is 
in contrast to the effect of total lipoprotein hydrolysis products, which significantly 
increased the expression of PLIN2 in THP-1 macrophages. These data are comparable to 
those by Varela et al. (189), who showed that TG-rich lipoproteins increased the perilipin 
2 protein in THP-1 macrophages. It is very likely that hydrolysis products other than FFA, 
specifically one or more molecular species of diacylglycerol and lysophospholipid, 
contribute to the expression of PLIN2; these expression remain to be identified. 
In addition to the expression of both CD36 and PLIN2 being upregulated in THP-
1 macrophages in response to total lipoprotein hydrolysis products generated by LPL, my 
microarray data also show an increased expression of CPT1A (which encodes carnitine 
palmitoyltransferase 1A) and FABP4 (which encodes fatty acid binding protein 4). In 
addition, the data show a decreased expression of ACAT2 (which encodes acetyl-CoA 
acetyltransferase 2), FASN (which encodes fatty acid synthase), and both FADS1 and 
FADS2 (which encode fatty acid desaturase 1 and 2, respectively). It was previously 
reported that lipoprotein hydrolysis products generated by LPL decrease the expression of 
FASN in THP-1 macrophages (77). Overall, the data for these other lipid metabolism genes 
suggest that THP-1 macrophages are attempting to process the excess lipid, likely by 
increasing intracellular fatty acid transport and increasing transfer of fatty acids into 
mitochondria for oxidation, while likely reducing lipid synthesis (Figure. 13). However,  
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Figure 16: Lipoprotein hydrolysis products generated by LPL modulates lipid-
associated genes 
Differentially expressed lipid metabolism genes in THP-1 macrophages in response to LPL 
hydrolysis products. Our microarray data showed that LPL hydrolysis products enhanced 
the expression levels of CD36, FABP4, PLIN2, and CPT1A in THP-1 macrophages. This 
suggests that some of the total lipoprotein hydrolysis products that are generated by LPL 
may be brought into the cells via CD36, the FFA component within the hydrolysis products 
may be shuttled within the cells by FABP4, and the FFA may be either brought to the 
mitochondria, where increased β-oxidation may be occurring (as suggested with the 
increase of CPT1A expression), or to be re-esterified into TG and stored in lipid droplets 
(as suggested with the increase of PLIN2 expression). On the other hand, our microarray 
data showed that genes associated with intracellular FFA synthesis (FASN, FADS1, and 
FADS2), isoprenoid biosynthesis (ACAT2), and low-density lipoprotein-cholesterol 
endocytosis (LDLR) were downregulated in response to LPL hydrolysis products. Up 
arrow (green) denotes an upregulated gene, whereas a down arrow (red) denoted a 
downregulated gene. The expression levels of genes that were also assessed in separate 
experiments via quantitative real-time PCR are underlined; the PCR data were similar to 
those from the microarray data. The quantitative real-time PCR analysis of FASN in 
response to LPL hydrolysis products was previously reported. 
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the cells continue to accumulate lipid (possibly via CD36 uptake) and store lipid (which 
accounts for an increase of PLIN2 expression), ultimately resulting in pathogenic foam cell 
formation. 
4.6 Study Limitations 
In this study, the array data showed increases in SNORA56/DKC1-v3 expression 
levels. To assess the gene expression using real-time PCR, primer sequences specific for 
both SNORA56 and DKC1-v3 were designed. Although the sequences did not overlap, it is 
hard to distinguish the effects of our treatment in modulating SNORA56 or DKC1-v3 alone, 
as SNORA56 sequences are retained within exon 12 of DKC1-v3. In my study, the relative 
expression levels of both these genes were comparable. This suggests that the observed 
effects of total lipoprotein hydrolysis products or FFA was only reflecting DKC1-v3 
expression. However, there is also a possibility that the expression of intronic SNORA56 
from other DKC1 variants was influenced.  
Microarray analyses were performed on THP-1 macrophages exposed to 0.68 mM 
LPL hydrolysis products, based on FFA content. However, the hydrolysis products 
incubated with macrophages is a complex mixture that contains wide range of lipids 
including cholesterol, CE, TG, monoglycerides, diglycerides, lysophospholipids, in 
addition to FFAs. Thus, the effects of LPL hydrolysis products in modulating macrophage 
transcript levels may not necessarily mimic the effects of FFA components within the 
hydrolysis products. Moreover, it is very hard to confirm which components in the 
hydrolysis products are responsible for altering each and every gene. Although the effects 
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of a purified FFA mixture or individual FFA classes in altering select genes were 
quantified, it does not provide a solid basis to understand the impact of FFA components 
within LPL hydrolysis products in foam cell formation.  
The use of microarrays provides a complete mRNA expression profile and they can 
cover non-coding RNA transcripts that may affect mRNA expression. However, they only 
provide information at the transcriptional level. The changes seen in mRNA expression 
may not necessarily mean that a similar trend will be observed with regards to protein 
translation and function. The gene expression is regulated post-transcriptionally and post-
translationally at different levels, and the half-lives of mRNA and protein vary. Thus, 
caution must be taken with the interpretations behind the transcriptomic data from THP-1 
macrophages in response to LPL hydrolysis products and FFA.  
4.7 Future Perspectives  
Recent studies have identified the emerging new non-canonical functions of 
snoRNA in addition to their role in ribosome synthesis (169). Interestingly, some snoRNA 
species have also shown to possess microRNA capabilities (190). Thus suggesting that 
snoRNAs can play a role in post-transcriptional modifications. My array data suggested 
that LPL hydrolysis products modulate several snoRNAs. The effects of the select 
snoRNAs could be studied in the context of atherosclerosis. Antisense oligonucleotides 
could be used to inhibit select snoRNA expression in macrophages and high-throughput 
sequencing, such as RNA sequencing, could be performed on macrophages exposed to 
purified FFA mixtures to comprehensively study their role in affecting genes associated 
with foam cell formation.  
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My study showed that the LPL hydrolysis products affect SNORA56/DKC1-v3 
expression in macrophages. The function of this specific variant is not yet clearly 
understood. Intron retention in DKC1-v3 suggests that this specific variant may also have 
a unique function. Studying the loss-of-function and the gain-of-function of DKC1-v3 in 
human macrophages in the presence of LPL hydrolysis products will provide us with 
insights on the role of these hydrolysis products in macrophage-derived foam cell 
formation. 
Suganami et al. (183) showed that the overexpression of ATF3 in RAW264 
macrophages suppresses the expression of the pro-inflammatory cytokine TNF-α. This 
suggests that the increased expression of this transcriptional repressor in LPL hydrolysis 
product-treated macrophages may be a feedback mechanism to suppress the expression of 
pro-inflammatory cytokines. Quantifying the protein levels of both ATF3 and TNF-α in 
macrophages exposed to LPL hydrolysis products is of future interest. Understanding how 
ATF3 controls the expression pro-inflammatory cytokines in macrophages will make it a 
therapeutic target in future. In vitro knockdown of ATF3 in human macrophages and then 
exposing to either LPL hydrolysis products or purified FFA mixture will help us unravel 
the underlying mechanisms in foam cell formation. 
4.8 Overall Conclusion 
This study has shown for the first time that LPL hydrolysis products may impair 
ribosome biogenesis by affecting non-coding snoRNA expression levels in human 
macrophages and, thus, opening windows for new perspectives into how LPL functions in 
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atherosclerosis. My data suggest that LPL hydrolysis products affect genes associated with 
cell cycling, stress response, and interferon type I signaling in THP-1 macrophages. The 
hydrolysis products that are generated by LPL from total lipoprotein lipids appear to 
positively affect processes in THP-1 macrophages that are associated with atherosclerosis. 
This is consistent with the known promotion of atherosclerosis by macrophage LPL, but 
my data provide some insight into the molecular mechanisms behind this process in the 
early stages of macrophage to foam cell conversion. Although the effects of total 
lipoprotein hydrolysis products generated by LPL appeared to not exclusively be the act of 
the FFA components in hydrolysis products, the FFA nonetheless did influence the 
expression of select genes in THP-1 macrophages. 
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R-studio Scripts: Functions used to obtain a list of differentially regulated genes in LPL hydrolysis 
product-treated macrophage cells. # represents the purpose of using any commands 
>setwd("~/R/nammiR/lplmicroarray") # to set working directory 
>source("https://bioconductor.org/biocLite.R") # source to find packages 
>biocLite("hugene20sttranscriptcluster.db") # to install the packeges 
>library(hugene20sttranscriptcluster.db) # package that is required analyze human gene array 
>library(oligo) # command that helps to read CEL file format 
>celfiles <- list.celfiles() # to load CEL files 
>celfiles 
>data <- read.celfiles(celfiles) # to read data in CEL file format 
>data 
>hist(data) # quality assessment step; histogram analyzes of raw data before normalization 
>boxplot(data) # quality assessment step; boxplot analysis of raw data before normalization 
>image(data) # gives image of raw data intensities 
>genes <- rma(data) # normalizes the data and performs background correction 
>genes 
>hist(genes) # histogram analyses of data after normalization 
>boxplot(genes) # boxplot analyses of data after normalization 
>library(limma) # package needed for analyses of differentially regulated genes 
>design <- model.matrix(~0+factor(c(1,1,1,2,2,2))) # function that creates a matrix design for 2 
treatments with 3 replicates 
>colnames(design) <- c("N","H") # command that assigns row or column names for matrix c, where 
N represents non-hydrolysis product and H represents hydrolysis product 
>design # function that helps to design a matrix 
>fit <-lmFit(genes, design) # function fits probeset in designed matrix 
>contrast.matrix <- makeContrasts(H-N,levels=design) # function compares LPL hydrolysis 
product treatment vs non-hydrolysis product treatment 
>contrast.matrix  
>fit2 <- contrasts.fit(fit, contrast.matrix) # function fits probeset in contrast adjusted matrix  
>fit3 <- eBayes(fit2) # eBayes function helps to rank differentially regulated genes in treatment 
>write.csv(fit3, file="results.csv") # command helps to write the matrix file in new file name 
‘results’ 
>results <- decideTests(fit3, p.value=0.05) # to get differentially regulated genes with a specific P. 
value 0.03 
>nar <- topTable(fit3, coef=1, n=10000, adjust="fdr", p.value=0.03) # extract table of top ranked 
genes linear model fit 
>head(nar) # Shows top 6 genes that are differentially expressed in a file ‘ttHP’ 
>write.csv(nar, file="nar.csv") # writes topTable transcript ID in CSV format 
 
Gene Annotation 
 
>getwd() # function confirms working directory  
>library(biomaRt) # to use biomaRt for gene annotation  
>ensembl <- useMart("ensembl") 
>listDatasets(ensembl) 
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>ensembl = useMart("ensembl",dataset="hsapiens_gene_ensembl") 
>filters = listFilters(ensembl) 
>attributes = listAttributes(ensembl) 
>affy<- read.csv("nar.csv",header=T) 
>LPLgenes<-getBM(attributes=c('affy_hugene_2_0_st_v1', 'hgnc_symbol', 'description'), filters = 
'affy_hugene_2_0_st_v1', values = affy, mart = ensembl) # to annotate genes in TopTable 
>write.csv(LPLgenes, file="LPLgenes.csv)      
124 
 
Appendix II: Supplementary tables 
 
 
 
 
  
125 
 
Table S1: Product length and amplification efficiencies of select gene-primers 
Gene Product length Efficiency (IQ 
SYBR) 
Efficiency (Sso 
advanced) 
ACTB 148 0.73 1.02 
ATF3 127 1.09 Not calculated 
ADRP 139 1.05 Not calculated 
CD36 131 0.89 Not calculated 
PCNA 125 0.95 Not calculated 
IFITM1 145 0.98 Not calculated 
SNORA75 135 1.08 Not calculated 
SNORA56 104 0.97 Not calculated 
DKC-v3 136 1.15 1.22 
 
The amplification efficiencies of the primers are mentioned above. Except DKC-v3 gene 
expression, transcript levels of other genes were measured using IQ SYBR green (Bio-
Rad) after LPL hydrolysis product treatment in THP-1 macrophages. To assess the 
expression of DKC1-v3, SsoAdvanced SYBR green (Bio-Rad) was used. 
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Table S2: List of up-regulated transcripts in LPL hydrolysis product treatment 
ID Gene symbol Gene Description Log2FC 
16913572 SNORA60 small nucleolar RNA, H/ACA box 60 [Source:HGNC Symbol;Acc:HGNC:32654] 3.5866661 
17070492 ATP6V0D2 ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d2 [Source:HGNC 
Symbol;Acc:HGNC:18266] 
2.7880616 
17038309 HSPA1B/HSPA1A heat shock 70kDa protein 1B [Source:HGNC Symbol;Acc:HGNC:5233]/ heat shock 
70kDa protein 1A [Source:HGNC Symbol;Acc:HGNC:5232] 
2.7216879 
16909520 SNORA75/ 
SNORD20/ NCL 
small nucleolar RNA, H/ACA box 75 [Source:HGNC Symbol;Acc:HGNC:32661]/ 
small nucleolar RNA, C/D box 20 [Source:HGNC Symbol;Acc:HGNC:10143]/ 
nucleolin [Source:HGNC Symbol;Acc:HGNC:7667] 
2.7216756 
17026331 HSPA1A/ HSPA1B heat shock 70kDa protein 1A [Source:HGNC Symbol;Acc:HGNC:5232]/ heat shock 
70kDa protein 1B [Source:HGNC Symbol;Acc:HGNC:5233] 
2.7068702 
16700713 SNORA14B small nucleolar RNA, H/ACA box 14B [Source:HGNC Symbol;Acc:HGNC:32603] 2.6892518 
17006863 HSPA1A/ HSPA1B heat shock 70kDa protein 1A [Source:HGNC Symbol;Acc:HGNC:5232]/ heat shock 
70kDa protein 1B [Source:HGNC Symbol;Acc:HGNC:5233] 
2.6840046 
17028007 HSPA1A/ HSPA1B heat shock 70kDa protein 1A [Source:HGNC Symbol;Acc:HGNC:5232]/ heat shock 
70kDa protein 1B [Source:HGNC Symbol;Acc:HGNC:5233] 
2.6584235 
16694357 SNORA80E small nucleolar RNA, H/ACA box 80E [Source:HGNC Symbol;Acc:HGNC:32635] 2.6564718 
17006881 HSPA1A/ HSPA1B heat shock 70kDa protein 1A [Source:HGNC Symbol;Acc:HGNC:5232]/ heat shock 
70kDa protein 1B [Source:HGNC Symbol;Acc:HGNC:5233] 
2.6275314 
17118411 --- --- 2.6227777 
17118415 --- --- 2.6227777 
17038297 HSPA1B/HSPA1A heat shock 70kDa protein 1B [Source:HGNC Symbol;Acc:HGNC:5233]/ heat shock 
70kDa protein 1A [Source:HGNC Symbol;Acc:HGNC:5232] 
2.5986065 
17026318 HSPA1A/ HSPA1B heat shock 70kDa protein 1A [Source:HGNC Symbol;Acc:HGNC:5232]/ heat shock 
70kDa protein 1B [Source:HGNC Symbol;Acc:HGNC:5233] 
2.5803337 
17027994 HSPA1A/ HSPA1B heat shock 70kDa protein 1A [Source:HGNC Symbol;Acc:HGNC:5232]/ heat shock 
70kDa protein 1B [Source:HGNC Symbol;Acc:HGNC:5233] 
2.5803337 
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17030820 HSPA1A/ HSPA1B heat shock 70kDa protein 1A [Source:HGNC Symbol;Acc:HGNC:5232]/ heat shock 
70kDa protein 1B [Source:HGNC Symbol;Acc:HGNC:5233] 
2.5803337 
17030833 HSPA1A/ HSPA1B heat shock 70kDa protein 1A [Source:HGNC Symbol;Acc:HGNC:5232]/ heat shock 
70kDa protein 1B [Source:HGNC Symbol;Acc:HGNC:5233] 
2.4877231 
17046094 RNU1-14P RNA, U1 small nuclear 14, pseudogene [Source:HGNC Symbol;Acc:HGNC:10139] 2.4656077 
17078592 FABP4 fatty acid binding protein 4, adipocyte [Source:HGNC Symbol;Acc:HGNC:3559] 2.4445675 
16837063 SNHG25/ 
SNORA76C 
small nucleolar RNA host gene 25 [Source:HGNC Symbol;Acc:HGNC:51534]/ small 
nucleolar RNA, H/ACA box 76C [Source:HGNC Symbol;Acc:HGNC:32662]/ Small 
nucleolar RNA SNORA50 [Source:RFAM;Acc:RF00407] 
2.3765251 
17104049 SNORA11 small nucleolar RNA, H/ACA box 11 [Source:HGNC Symbol;Acc:HGNC:32599] 2.3553409 
16763966 SNORA2A small nucleolar RNA, H/ACA box 2A [Source:HGNC Symbol;Acc:HGNC:32584] 2.2757955 
16691331 SNORA42 Small nucleolar RNA SNORA42/SNORA80 family [Source:RFAM;Acc:RF00406] 2.2552694 
17012711 SNORA33 small nucleolar RNA, H/ACA box 33 [Source:HGNC Symbol;Acc:HGNC:32623] 2.2304004 
17116675 --- --- 2.2272587 
16702705 OLAH oleoyl-ACP hydrolase [Source:HGNC Symbol;Acc:HGNC:25625] 2.2220248 
16846359 RNU1-42P RNA, U1 small nuclear 42, pseudogene [Source:HGNC Symbol;Acc:HGNC:48384] 2.2037127 
17092710 SCARNA8 small Cajal body-specific RNA 8 [Source:HGNC Symbol;Acc:HGNC:32564] 2.1576388 
17119802 DKC1/ SNORA56 dyskeratosis congenita 1, dyskerin [Source:HGNC Symbol;Acc:HGNC:2890]/ small 
nucleolar RNA, H/ACA box 56 [Source:HGNC Symbol;Acc:HGNC:32650] 
2.0804498 
16694359 SCARNA4 small Cajal body-specific RNA 4 [Source:HGNC Symbol;Acc:HGNC:32560] 2.0437777 
17059955 PDK4 pyruvate dehydrogenase kinase, isozyme 4 [Source:HGNC Symbol;Acc:HGNC:8812] 2.0370528 
16919223 SNORA71B small nucleolar RNA, H/ACA box 71B [Source:HGNC Symbol;Acc:HGNC:10233] 2.0075156 
16661646 RNU11 RNA, U11 small nuclear [Source:HGNC Symbol;Acc:HGNC:10108] 2.0064381 
17100695 MT-TS1 mitochondrially encoded tRNA serine 1 (UCN) [Source:HGNC 
Symbol;Acc:HGNC:7497] 
2.0015946 
16878583 SNORD92 small nucleolar RNA, C/D box 92 [Source:HGNC Symbol;Acc:HGNC:32754] 2.000231 
16696685 SCARNA3 small Cajal body-specific RNA 3 [Source:HGNC Symbol;Acc:HGNC:32577] 1.9633422 
16650847 --- --- 1.9607653 
16800297 RNU6-353P RNA, U6 small nuclear 353, pseudogene [Source:HGNC Symbol;Acc:HGNC:47316] 1.9267232 
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17119340 SNORA6/ RPSA small nucleolar RNA, H/ACA box 6 [Source:HGNC Symbol;Acc:HGNC:32591]/ 
ribosomal protein SA [Source:HGNC Symbol;Acc:HGNC:6502] 
1.9105746 
16943230 LINC00973 long intergenic non-protein coding RNA 973 [Source:HGNC 
Symbol;Acc:HGNC:48868] 
1.8895967 
16826966 SNORA46 small nucleolar RNA, H/ACA box 46 [Source:HGNC Symbol;Acc:HGNC:32639] 1.8595548 
17119224 SNORA41/ 
SNORD51/ 
EEF1B2 
small nucleolar RNA, H/ACA box 41 [Source:HGNC Symbol;Acc:HGNC:32634]/ 
small nucleolar RNA, C/D box 51 [Source:HGNC Symbol;Acc:HGNC:10201]/ 
eukaryotic translation elongation factor 1 beta 2 [Source:HGNC 
Symbol;Acc:HGNC:3208]/  Small nucleolar RNA Z196/R39/R59 family 
[Source:RFAM;Acc:RF00134] 
1.8408576 
16734524 SNORA54 small nucleolar RNA, H/ACA box 54 [Source:HGNC Symbol;Acc:HGNC:32647] 1.8271199 
16676682 IL24 interleukin 24 [Source:HGNC Symbol;Acc:HGNC:11346] 1.7993536 
16837226 SNORA38B small nucleolar RNA, H/ACA box 38B [Source:HGNC Symbol;Acc:HGNC:33617] 1.7666499 
16992465 SNORA74B/ 
ATP6V0E1 
small nucleolar RNA, H/ACA box 74B [Source:HGNC Symbol;Acc:HGNC:32660]/ 
ATPase, H+ transporting, lysosomal 9kDa, V0 subunit e1 [Source:HGNC 
Symbol;Acc:HGNC:863] 
1.7585149 
16992466 SNORA74B small nucleolar RNA, H/ACA box 74B [Source:HGNC Symbol;Acc:HGNC:32660] 1.7585149 
17079434 SNORA72/ RPL30 small nucleolar RNA, H/ACA box 72 [Source:HGNC Symbol;Acc:HGNC:10234]/ 
ribosomal protein L30 [Source:HGNC Symbol;Acc:HGNC:10333] 
1.7416766 
17079435 SNORA72/ RPL30 small nucleolar RNA, H/ACA box 72 [Source:HGNC Symbol;Acc:HGNC:10234]/ 
ribosomal protein L30 [Source:HGNC Symbol;Acc:HGNC:10333] 
1.7416766 
17021510 CNR1 cannabinoid receptor 1 (brain) [Source:HGNC Symbol;Acc:HGNC:2159] 1.7297764 
17119488 SNORA20/ TCP1 small nucleolar RNA, H/ACA box 20 [Source:HGNC Symbol;Acc:HGNC:32610]/ t-
complex 1 [Source:HGNC Symbol;Acc:HGNC:11655] 
1.7272721 
16977868 ABCG2 ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group) 
[Source:HGNC Symbol;Acc:HGNC:74] 
1.713334 
16837061 SNORD104 small nucleolar RNA, C/D box 104 [Source:HGNC Symbol;Acc:HGNC:32768] 1.7079617 
17021504 CNR1 cannabinoid receptor 1 (brain) [Source:HGNC Symbol;Acc:HGNC:2159] 1.6914375 
17016025 RNU6-801P RNA, U6 small nuclear 801, pseudogene [Source:HGNC Symbol;Acc:HGNC:47764] 1.6740173 
16732345 RNU6-1123P RNA, U6 small nuclear 1123, pseudogene [Source:HGNC Symbol;Acc:HGNC:48086] 1.6567592 
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16847393 SCARNA20 small Cajal body-specific RNA 20 [Source:HGNC Symbol;Acc:HGNC:32578] 1.6468453 
17085901 ANXA1 annexin A1 [Source:HGNC Symbol;Acc:HGNC:533] 1.6458665 
16842237 SNORD3C small nucleolar RNA, C/D box 3C [Source:HGNC Symbol;Acc:HGNC:33191] 1.6442244 
16747336 SCARNA10 small Cajal body-specific RNA 10 [Source:HGNC Symbol;Acc:HGNC:32567] 1.6229055 
16997793 SCARNA18 small Cajal body-specific RNA 18 [Source:HGNC Symbol;Acc:HGNC:32559] 1.6159547 
16904022 RNU6-580P RNA, U6 small nuclear 580, pseudogene [Source:HGNC Symbol;Acc:HGNC:47543] 1.6153682 
16969988 RNU1-138P/ 
RN7SL184P 
RNA, U1 small nuclear 138, pseudogene [Source:HGNC Symbol;Acc:HGNC:48480]/ 
RNA, 7SL, cytoplasmic 184, pseudogene [Source:HGNC Symbol;Acc:HGNC:46200] 
1.6128574 
16919229 SNORA71D small nucleolar RNA, H/ACA box 71D [Source:HGNC Symbol;Acc:HGNC:32657] 1.6022969 
17047459 SNORA14A small nucleolar RNA, H/ACA box 14A [Source:HGNC Symbol;Acc:HGNC:32602] 1.5993334 
16741287 CPT1A carnitine palmitoyltransferase 1A (liver) [Source:HGNC Symbol;Acc:HGNC:2328] 1.5958596 
16899758 RNU1-38P RNA, U1 small nuclear 38, pseudogene [Source:HGNC Symbol;Acc:HGNC:48380] 1.5788866 
17119236 RNU1-38P RNA, U1 small nuclear 38, pseudogene [Source:HGNC Symbol;Acc:HGNC:48380] 1.5788866 
16677278 ATF3 activating transcription factor 3 [Source:HGNC Symbol;Acc:HGNC:785] 1.5618703 
17047795 CD36 Cluster of differentiation 36 1.5612921 
16892523 SCARNA6 small Cajal body-specific RNA 6 [Source:HGNC Symbol;Acc:HGNC:32562] 1.5516909 
17092712 PLIN2 Perilipin 2 1.5503564 
16721732 SNORA45B small nucleolar RNA, H/ACA box 45B [Source:HGNC Symbol;Acc:HGNC:32638] 1.5448671 
16822904 SNORA64/ 
SNORA10/ RPS2 
small nucleolar RNA, H/ACA box 64 [Source:HGNC Symbol;Acc:HGNC:10221]/ 
small nucleolar RNA, H/ACA box 10 [Source:HGNC Symbol;Acc:HGNC:32598]/ 
ribosomal protein S2 [Source:HGNC Symbol;Acc:HGNC:10404] 
1.5310674 
16688022 RNU6-371P RNA, U6 small nuclear 371, pseudogene [Source:HGNC Symbol;Acc:HGNC:47334] 1.5209346 
16808555 RNU1-119P/ 
RNU1-78P 
RNA, U1 small nuclear 119, pseudogene [Source:HGNC Symbol;Acc:HGNC:48461]/ 
RNA, U1 small nuclear 78, pseudogene [Source:HGNC Symbol;Acc:HGNC:48420] 
1.5208139 
16881353 DYSF dysferlin [Source:HGNC Symbol;Acc:HGNC:3097] 1.5186063 
16793674 HIF1A-AS2 HIF1A antisense RNA 2 [Source:HGNC Symbol;Acc:HGNC:43015] 1.5170582 
16855340 SNORA37 small nucleolar RNA, H/ACA box 37 [Source:HGNC Symbol;Acc:HGNC:32630] 1.5107854 
16948967 SNORD66 small nucleolar RNA, C/D box 66 [Source:HGNC Symbol;Acc:HGNC:32727] 1.5060778 
16985704 OCLN occludin [Source:HGNC Symbol;Acc:HGNC:8104] 1.4780406 
17009627 RN7SK RNA, 7SK small nuclear [Source:HGNC Symbol;Acc:HGNC:10037] 1.4471638 
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17118690 SNORA61/ 
SNORA44/ 
SNHG12 
small nucleolar RNA, H/ACA box 61 [Source:HGNC Symbol;Acc:HGNC:32655]/ 
small nucleolar RNA, H/ACA box 44 [Source:HGNC Symbol;Acc:HGNC:32637]/ 
small nucleolar RNA host gene 12 [Source:HGNC Symbol;Acc:HGNC:30062] 
1.4452369 
16725908 METTL12/ 
SNORA57 
methyltransferase like 12 [Source:HGNC Symbol;Acc:HGNC:33113]/ small nucleolar 
RNA, H/ACA box 57 
1.4413508 
16726880 NEAT1 nuclear paraspeckle assembly transcript 1 (non-protein coding) [Source:HGNC 
Symbol;Acc:HGNC:30815] 
1.4348734 
16756078 MIR3652/ 
HSP90B1 
microRNA 3652 [Source:HGNC Symbol;Acc:HGNC:38894]/ heat shock protein 
90kDa beta (Grp94),member 1[Acc: HGNC: 12028] 
1.4287571 
17057422 SNORA9/ SNHG15 small nucleolar RNA, H/ACA box 9 [Source:HGNC Symbol;Acc:HGNC:32597]/ 
small nucleolar RNA host gene 15 [Source:HGNC Symbol;Acc:HGNC:27797] 
1.4272427 
16745561 SNORD14E/ 
HSPA8 
small nucleolar RNA, C/D box 14E [Source:HGNC Symbol;Acc:HGNC:30354]/ heat 
shock 70kDa protein 8 [Source:HGNC Symbol;Acc:HGNC:5241] 
1.4184116 
16892521 SCARNA5 small Cajal body-specific RNA 5 [Source:HGNC Symbol;Acc:HGNC:32561] 1.4166707 
16650739 --- --- 1.4156 
17118778 SNORA52/ RPLP2 small nucleolar RNA, H/ACA box 52 [Source:HGNC Symbol;Acc:HGNC:32645]/ 
ribosomal protein, large, P2 [Source:HGNC Symbol;Acc:HGNC:10377] 
1.411497 
16849274 ST6GALNAC2 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide 
alpha-2,6-sialyltransferase 2 [Source:HGNC Symbol;Acc:HGNC:10867] 
1.4111302 
16989863 SNORA74A small nucleolar RNA, H/ACA box 74A [Source:HGNC Symbol;Acc:HGNC:10119] 1.4061698 
16984408 --- --- 1.3952916 
16917849 THBD thrombomodulin [Source:HGNC Symbol;Acc:HGNC:11784] 1.3641165 
16984689 ITGA2 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) [Source:HGNC 
Symbol;Acc:HGNC:6137] 
1.356986 
16914741 SNORD12C small nucleolar RNA, C/D box 12C [Source:HGNC Symbol;Acc:HGNC:10105] 1.3563469 
17059087 RNU6-530P RNA, U6 small nuclear 530, pseudogene [Source:HGNC Symbol;Acc:HGNC:47493] 1.3500675 
17021489 --- --- 1.348503 
16798665 GOLGA8J golgin A8 family, member J [Source:HGNC Symbol;Acc:HGNC:38650] 1.3450867 
16655929 --- --- 1.3410729 
16892075 ARMC9 armadillo repeat containing 9 [Source:HGNC Symbol;Acc:HGNC:20730] 1.3246787 
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16777185 GJB2 gap junction protein, beta 2, 26kDa [Source:HGNC Symbol;Acc:HGNC:4284] 1.3239012 
16752024 COPZ1 Coatomer Protein Complex, Subunit Zeta 1[Source:HGNC Symbol;Acc:HGNC:2243] 1.3238051 
17119260 SNORA51/ 
NOP56/ 
SNORD110 
small nucleolar RNA, H/ACA box 51 [Source:HGNC Symbol;Acc:HGNC:32644]/ 
NOP56 ribonucleoprotein [Source:HGNC Symbol;Acc:HGNC:15911]/ small nucleolar 
RNA, C/D box 110 [Source:HGNC Symbol;Acc:HGNC:32775]/ Small nucleolar RNA 
SNORA51 [Source:RFAM;Acc:RF00432] 
1.3226882 
16654979 --- --- 1.2894301 
16867349 SEMA6B sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 
6B [Source:HGNC Symbol;Acc:HGNC:10739] 
1.270519 
17020608 ERVH-3 endogenous retrovirus group H member 3 [Source:HGNC Symbol;Acc:HGNC:39055] 1.2634586 
17126140 --- --- 1.2619936 
16878674 SNORA64/ 
SNORA10 
Small nucleolar RNA SNORA64/SNORA10 family [Source:RFAM;Acc:RF00264] 1.2599949 
16852666 SEC11C SEC11 homolog C (S. cerevisiae) [Source:HGNC Symbol;Acc:HGNC:23400] 1.2522244 
17124336 --- --- 1.2491668 
17099678 RNU6ATAC2P/ 
RNU6ATAC 
RNA, U6atac small nuclear 2, pseudogene [Source:HGNC 
Symbol;Acc:HGNC:34092]/ RNA, U6atac small nuclear (U12-dependent splicing) 
[Source:HGNC Symbol;Acc:HGNC:34017] 
1.2425555 
16832031 SNORD3D/ 
SNORD3B-2/  
SNORD3B-1/ 
SNORD3C/ 
SNORD3A 
small nucleolar RNA, C/D box 3D [Source:HGNC Symbol;Acc:HGNC:33192]/ small 
nucleolar RNA, C/D box 3B-2 [Source:HGNC Symbol;Acc:HGNC:33190]/ small 
nucleolar RNA, C/D box 3B-1 [Source:HGNC Symbol;Acc:HGNC:10168]/ small 
nucleolar RNA, C/D box 3C [Source:HGNC Symbol;Acc:HGNC:33191]/ small 
nucleolar RNA, C/D box 3A [Source:HGNC Symbol;Acc:HGNC:33189] 
1.2419421 
16832005 SNORD3C/ 
SNORD3A/ 
SNORD3D/ 
SNORD3B-1/ 
SNORD3B-2 
small nucleolar RNA, C/D box 3C [Source:HGNC Symbol;Acc:HGNC:33191]/ small 
nucleolar RNA, C/D box 3A [Source:HGNC Symbol;Acc:HGNC:33189]/ small 
nucleolar RNA, C/D box 3D [Source:HGNC Symbol;Acc:HGNC:33192]/ small 
nucleolar RNA, C/D box 3B-1 [Source:HGNC Symbol;Acc:HGNC:10168]/ small 
nucleolar RNA, C/D box 3B-2 [Source:HGNC Symbol;Acc:HGNC:33190] 
1.2397501 
16842215 SNORD3D/ 
SNORD3B-2/  
small nucleolar RNA, C/D box 3D [Source:HGNC Symbol;Acc:HGNC:33192]/ small 
nucleolar RNA, C/D box 3A [Source:HGNC Symbol;Acc:HGNC:33189]/ small 
1.2397501 
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SNORD3B-1/ 
SNORD3A 
nucleolar RNA, C/D box 3B-1 [Source:HGNC Symbol;Acc:HGNC:10168]/ small 
nucleolar RNA, C/D box 3B-2 [Source:HGNC Symbol;Acc:HGNC:33190] 
16661149 CD52 CD52 molecule [Source:HGNC Symbol;Acc:HGNC:1804] 1.2345235 
16917529 SNORD17 small nucleolar RNA, C/D box 17 [Source:HGNC Symbol;Acc:HGNC:32713] 1.2270778 
17009661 RNU1-136P RNA, U1 small nuclear 136, pseudogene [Source:HGNC Symbol;Acc:HGNC:48478] 1.2262186 
16988913 RNU6ATAC10P RNA, U6atac small nuclear 10, pseudogene [Source:HGNC 
Symbol;Acc:HGNC:46909] 
1.2178176 
16778713 TPT1 tumor protein, translationally-controlled 1 [Source:HGNC 
Symbol;Acc:HGNC:12022]/ Small nucleolar RNA SNORA31 [Acc: RF00322] 
1.2157673 
17118780 SNORA45A/ 
RPL27A 
small nucleolar RNA, H/ACA box 45A [Source:HGNC Symbol;Acc:HGNC:32586]/ 
ribosomal protein L27a [Source:HGNC Symbol;Acc:HGNC:10329] 
1.2108397 
16874643 SNORD88A small nucleolar RNA, C/D box 88A [Source:HGNC Symbol;Acc:HGNC:32747] 1.2094201 
16972249 PALLD palladin, cytoskeletal associated protein [Source:HGNC Symbol;Acc:HGNC:17068] 1.2077975 
17015472 SCARNA27 small Cajal body-specific RNA 27 [Source:HGNC Symbol;Acc:HGNC:33614] 1.2047601 
16996347 RNU6ATAC2P/ 
RNU6ATAC 
RNA, U6atac small nuclear 2, pseudogene [Source:HGNC 
Symbol;Acc:HGNC:34092]/ RNA, U6atac small nuclear (U12-dependent splicing) 
[Source:HGNC Symbol;Acc:HGNC:34017] 
1.2032134 
16763964 SNORA34 small nucleolar RNA, H/ACA box 34 [Source:HGNC Symbol;Acc:HGNC:32624] 1.1952417 
16732807 VWA5A von Willebrand factor A domain containing 5A [Source:HGNC 
Symbol;Acc:HGNC:6658] 
1.1886058 
17118694 SNORA16A/ 
SNHG12 
small nucleolar RNA, H/ACA box 16A [Source:HGNC Symbol;Acc:HGNC:32605]/ 
small nucleolar RNA host gene 12 [Source:HGNC Symbol;Acc:HGNC:30062] 
1.1865771 
17064135 PDIA4 protein disulfide isomerase family A, member 4 [Source:HGNC 
Symbol;Acc:HGNC:30167] 
1.1839374 
17027880 SNORA38 small nucleolar RNA, H/ACA box 38 [Source:HGNC Symbol;Acc:HGNC:32631] 1.1837403 
17033410 SNORA38 small nucleolar RNA, H/ACA box 38 [Source:HGNC Symbol;Acc:HGNC:32631] 1.1837403 
17038203 SNORA38 small nucleolar RNA, H/ACA box 38 [Source:HGNC Symbol;Acc:HGNC:32631] 1.1837403 
17040798 SNORA38 small nucleolar RNA, H/ACA box 38 [Source:HGNC Symbol;Acc:HGNC:32631] 1.1837403 
17098411 HSPA5 heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) [Source:HGNC 
Symbol;Acc:HGNC:5238] 
1.1779852 
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16929562 HMOX1 heme oxygenase 1 [Source:HGNC Symbol;Acc:HGNC:5013] 1.1458621 
16684581 SPOCD1 SPOC domain containing 1 [Source:HGNC Symbol;Acc:HGNC:26338] 1.1432937 
16961947 RNA5SP150 RNA, 5S ribosomal pseudogene 150 [Source:HGNC Symbol;Acc:HGNC:43050] 1.1322181 
17120056 PDE4DIP phosphodiesterase 4D interacting protein [Source:HGNC Symbol;Acc:HGNC:15580] 1.1314978 
16961037 SCARNA7 small Cajal body-specific RNA 7 [Source:HGNC Symbol;Acc:HGNC:32563] 1.1314575 
16651537 --- --- 1.1265227 
17054328 ZFAND2A zinc finger, AN1-type domain 2A [Source:HGNC Symbol;Acc:HGNC:28073] 1.1047416 
17118848 SNORA25/ 
TAF1D/ SNORD6/ 
SNORA32 
small nucleolar RNA, H/ACA box 25 [Source:HGNC Symbol;Acc:HGNC:32615]/ 
TATA box binding protein (TBP)-associated factor, RNA polymerase I, D, 41kDa 
[Source:HGNC Symbol;Acc:HGNC:28759]/ small nucleolar RNA, C/D box 6 
[Source:HGNC Symbol;Acc:HGNC:32703]/  small nucleolar RNA, H/ACA box 32 
[Source:HGNC Symbol;Acc:HGNC:32622] 
1.0932321 
16685702 SNORA55 small nucleolar RNA, H/ACA box 55 [Source:HGNC Symbol;Acc:HGNC:32649] 1.0832591 
16930066 KDELR3 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 3 
[Source:HGNC Symbol;Acc:HGNC:6306] 
1.0729487 
16970894 RNU6-1214P RNA, U6 small nuclear 1214, pseudogene [Source:HGNC Symbol;Acc:HGNC:48177] 1.0618682 
16889629 SNORD11B/ 
NOP58 
small nucleolar RNA, C/D box 11B [Source:HGNC Symbol;Acc:HGNC:33571]/ 
NOP58 ribonucleoprotein [Source:HGNC Symbol;Acc:HGNC:29926] 
1.0576988 
16948561  SNORA63 Small nucleolar RNA, H/ACA box 63 [Source:RFAM;Acc:RF00092] 1.0531162 
17010354 CD109 CD109 molecule [Source:HGNC Symbol;Acc:HGNC:21685] 1.0490491 
16869653 DNAJB1 DnaJ (Hsp40) homolog, subfamily B, member 1 [Source:HGNC 
Symbol;Acc:HGNC:5270] 
1.0209808 
16891082 CYP27A1 cytochrome P450, family 27, subfamily A, polypeptide 1 [Source:HGNC 
Symbol;Acc:HGNC:2605] 
1.01658 
16830302 ACADVL acyl-CoA dehydrogenase, very long chain [Source:HGNC Symbol;Acc:HGNC:92] 1.0048522 
17100967 --- --- 0.9936192 
16889631 SNORD11 small nucleolar RNA, C/D box 11 [Source:HGNC Symbol;Acc:HGNC:32707] 0.986239 
16829683 --- --- 0.9832682 
16815807 ATF7IP2 activating transcription factor 7 interacting protein 2 [Source:HGNC 
Symbol;Acc:HGNC:20397] 
0.9825237 
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16997399 SNORA47 small nucleolar RNA, H/ACA box 47 [Source:HGNC Symbol;Acc:HGNC:32640] 0.9789526 
16655723 --- --- 0.9788117 
17118876 SNORA53/ 
SLC25A3 
small nucleolar RNA, H/ACA box 53 [Source:HGNC Symbol;Acc:HGNC:32646]/ 
solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 3 
[Source:HGNC Symbol;Acc:HGNC:10989] 
0.9605636 
16931569 CRELD2 cysteine-rich with EGF-like domains 2 [Source:HGNC Symbol;Acc:HGNC:28150] 0.9579686 
16808296 RNU6-354P/ 
RNU6-610 
RNA, U6 small nuclear 354, pseudogene [Source:HGNC Symbol;Acc:HGNC:47317]/ 
RNA, U6 small nuclear 610, pseudogene [Source:HGNC Symbol;Acc:HGNC:47573] 
0.9538288 
16808338 RNU6-354P/ 
RNU6-610 
RNA, U6 small nuclear 354, pseudogene [Source:HGNC Symbol;Acc:HGNC:47317]/ 
RNA, U6 small nuclear 610, pseudogene [Source:HGNC Symbol;Acc:HGNC:47573] 
0.9538288 
16745186 HYOU1 hypoxia up-regulated 1 [Source:HGNC Symbol;Acc:HGNC:16931] 0.9466647 
17006743 SNORA38 small nucleolar RNA, H/ACA box 38 [Source:HGNC Symbol;Acc:HGNC:32631] 0.9447982 
17121352 SNX29P1/ SNX29/ 
SNX29P2 
sorting nexin 29 pseudogene 1 [Source:HGNC Symbol;Acc:HGNC:31913]/ sorting 
nexin 29 [Source:HGNC Symbol;Acc:HGNC:30542]/ sorting nexin 29 pseudogene 2 
[Source:HGNC Symbol;Acc:HGNC:31914] 
0.9433485 
16795394 SEL1L sel-1 suppressor of lin-12-like (C. elegans) [Source:HGNC 
Symbol;Acc:HGNC:10717] 
0.9421456 
16858118 SNORD105 small nucleolar RNA, C/D box 105 [Source:HGNC Symbol;Acc:HGNC:32769] 0.94159 
16886564 FMNL2 formin-like 2 [Source:HGNC Symbol;Acc:HGNC:18267] 0.9222717 
16656633 --- --- 0.9221184 
16737841 SNORD67 small nucleolar RNA, C/D box 67 [Source:HGNC Symbol;Acc:HGNC:32728] 0.9132485 
17076220 LOC100507403 uncharacterized LOC100507403[Source:HGNC Symbol;Acc:HGNC:100507403] 0.9100782 
16670210 RNVU1-19 RNA, variant U1 small nuclear 19 [Source:HGNC Symbol;Acc:HGNC:48324] 0.9084498 
16953753 SLC25A20 solute carrier family 25 (carnitine/acylcarnitine translocase), member 20 
[Source:HGNC Symbol;Acc:HGNC:1421] 
0.9064836 
16748788 MGST1 Microsomal Glutathione S-Transferase 1[Source:HGNC Symbol;Acc:HGNC:7061] 0.8992862 
16780929 COL4A1 collagen, type IV, alpha 1 [Source:HGNC Symbol;Acc:HGNC:2202] 0.8972641 
16980051 CLGN calmegin [Source:HGNC Symbol;Acc:HGNC:2060] 0.8671733 
16890473 SNORA70 Small nucleolar RNA 70 [Source:RFAM;Acc:RF00156] 0.8153768 
16878585 SNORD53 small nucleolar RNA, C/D box 53 [Source:HGNC Symbol;Acc:HGNC:10203] 0.8056947 
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16689752 GCLM glutamate-cysteine ligase, modifier subunit [Source:HGNC Symbol;Acc:HGNC:4312] 0.7862908 
17025659 RPS6KA2-IT1 RPS6KA2 intronic transcript 1 [Source:HGNC Symbol;Acc:HGNC:41378] 0.77634 
16947850 GPR160 G protein-coupled receptor 160 [Source:HGNC Symbol;Acc:HGNC:23693] 0.7666492 
16700456 FAM89A family with sequence similarity 89, member A [Source:HGNC 
Symbol;Acc:HGNC:25057] 
0.7651809 
17088124 HSDL2 hydroxysteroid dehydrogenase like 2 [Source:HGNC Symbol;Acc:HGNC:18572] 0.7485383 
 
THP-1 macrophages were incubated with LPL hydrolysis products or non-hydrolysis products for 18 h. RNA from the treated 
cells were subjected to human gene 2.0ST array (n=3). Using R studio, a top list of up-regulated genes in LPL hydrolysis product 
treated macrophages were obtained at FDR ≤0.03. Log2FC represents 2-fold change of modulated transcript in macrophages 
treated with LPL hydrolysis products compared to control. 
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Table S3: List of down-regulated transcripts in LPL hydrolysis product treatment 
ID Gene symbol Gene Description Log2FC 
16666485 IFI44L interferon-induced protein 44-like -3.40455 
17011886 --- --- -2.84948 
17002328 IL12B interleukin 12B [Source:HGNC Symbol;Acc:HGNC:5970] -2.70207 
16651207 --- --- -2.36415 
16826634 RP11-212I21.2 Novel transcript -2.34831 
16977052 CXCL10 chemokine (C-X-C motif) ligand 10 [Source:HGNC Symbol;Acc:HGNC:10637] -2.18077 
16799739 CHAC1 ChaC glutathione-specific gamma-glutamylcyclotransferase 1 [Source:HGNC 
Symbol;Acc:HGNC:28680] 
-2.17631 
16720085 IFITM1 interferon induced transmembrane protein 1 [Source:HGNC Symbol;Acc:HGNC:5412] -2.17551 
17055786 AC073072.5 Novel transcript -1.9856 
16978779 DKK2 dickkopf WNT signaling pathway inhibitor 2 [Source:HGNC 
Symbol;Acc:HGNC:2892] 
-1.95953 
17031178 HLA-DQA2 major histocompatibility complex, class II, DQ alpha 2 [Source:HGNC 
Symbol;Acc:HGNC:4943] 
-1.90379 
17033646 HLA-DQA2 major histocompatibility complex, class II, DQ alpha 2 [Source:HGNC 
Symbol;Acc:HGNC:4943] 
-1.89539 
17038629 HLA-DQA2 major histocompatibility complex, class II, DQ alpha 2 [Source:HGNC 
Symbol;Acc:HGNC:4943] 
-1.88352 
17007292 HLA-DQA2 major histocompatibility complex, class II, DQ alpha 2 [Source:HGNC 
Symbol;Acc:HGNC:4943] 
-1.87547 
17028345 HLA-DQA2 major histocompatibility complex, class II, DQ alpha 2 [Source:HGNC 
Symbol;Acc:HGNC:4943] 
-1.84619 
16725041 FAM111B family with sequence similarity 111, member B [Source:HGNC 
Symbol;Acc:HGNC:24200] 
-1.81466 
16843309 CCL1 chemokine (C-C motif) ligand 1 [Source:HGNC Symbol;Acc:HGNC:10609] -1.8101 
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17041260 HLA-DQA2 major histocompatibility complex, class II, DQ alpha 2 [Source:HGNC 
Symbol;Acc:HGNC:4943] 
-1.80845 
17035918 HLA-DQA2 major histocompatibility complex, class II, DQ alpha 2 [Source:HGNC 
Symbol;Acc:HGNC:4943] 
-1.78535 
17044177 IL6 interleukin 6 [Source:HGNC Symbol;Acc:HGNC:6018] -1.72362 
17013694 PLEKHG1 pleckstrin homology domain containing, family G (with RhoGef domain) member 1 
[Source:HGNC Symbol;Acc:HGNC:20884] 
-1.68931 
16677201 DTL denticleless E3 ubiquitin protein ligase homolog (Drosophila) [Source:HGNC 
Symbol;Acc:HGNC:30288] 
-1.68798 
16767306 RP11-81H14.2 Novel transcript -1.68462 
16757373 OAS2 2'-5'-oligoadenylate synthetase 2, 69/71kDa [Source:HGNC Symbol;Acc:HGNC:8087] -1.66236 
16771535 KDM2B Lysine (K)-Specific Demethylase 2B [Source:HGNC Symbol;Acc:HGNC:13610] -1.66136 
17012959 RP11-240M16.1 Novel transcript -1.60761 
16852312 SKA1 spindle and kinetochore associated complex subunit 1 [Source:HGNC 
Symbol;Acc:HGNC:28109] 
-1.59535 
16988441 CTC-546K23.1 Novel transcript -1.56669 
16691327 NGF nerve growth factor (beta polypeptide) [Source:HGNC Symbol;Acc:HGNC:7808] -1.5156 
16965346 NCAPG non-SMC condensin I complex, subunit G [Source:HGNC Symbol;Acc:HGNC:24304] -1.50886 
16979515 CCNA2 cyclin A2 [Source:HGNC Symbol;Acc:HGNC:1578] -1.48705 
16877019 RRM2 ribonucleotide reductase M2 [Source:HGNC Symbol;Acc:HGNC:10452] -1.4867 
16990138 IK/ MIR3655 IK cytokine/ down-regulator of HLA 2 MIR3655 -1.48067 
16716371 CH25H cholesterol 25-hydroxylase [Source:HGNC Symbol;Acc:HGNC:1907] -1.47679 
17121988 --- --- -1.46159 
16912379 TPX2 TPX2, microtubule-associated [Source:HGNC Symbol;Acc:HGNC:1249] -1.44848 
16830202 XAF1 XIAP associated factor 1 [Source:HGNC Symbol;Acc:HGNC:30932] -1.4443 
17014361 MAS1 MAS1 proto-oncogene, G protein-coupled receptor [Source:HGNC 
Symbol;Acc:HGNC:6899] 
-1.43399 
16757347 OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa [Source:HGNC Symbol;Acc:HGNC:8088] -1.43037 
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16922959 MX2 MX Dynamin-Like GTPase 2[Source:HGNC Symbol;Acc:HGNC:7533] -1.40598 
16916605 CPXM1 carboxypeptidase X (M14 family), member 1 [Source:HGNC 
Symbol;Acc:HGNC:15771] 
-1.37974 
16844312 TOP2A topoisomerase (DNA) II alpha 170kDa [Source:HGNC Symbol;Acc:HGNC:11989] -1.36849 
16757324 OAS1 2'-5'-oligoadenylate synthetase 1, 40/46kDa [Source:HGNC Symbol;Acc:HGNC:8086] -1.34118 
16850477 TYMS thymidylate synthetase [Source:HGNC Symbol;Acc:HGNC:12441] -1.32701 
17067332 ESCO2 establishment of sister chromatid cohesion N-acetyltransferase 2 [Source:HGNC 
Symbol;Acc:HGNC:27230] 
-1.31974 
16799598 CASC5 cancer susceptibility candidate 5 [Source:HGNC Symbol;Acc:HGNC:24054] -1.30174 
17079293 CCNE2 cyclin E2 [Source:HGNC Symbol;Acc:HGNC:1590] -1.2966 
17012804 MYB v-myb avian myeloblastosis viral oncogene homolog [Source:HGNC 
Symbol;Acc:HGNC:7545] 
-1.27778 
16894127 CMPK2 cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial [Source:HGNC 
Symbol;Acc:HGNC:27015] 
-1.27582 
16976891 RP11-44F21.5 Novel transcript -1.27541 
16962022 LAMP3 lysosomal-associated membrane protein 3 [Source:HGNC Symbol;Acc:HGNC:14582] -1.26724 
16719515 MKI67 marker of proliferation Ki-67 [Source:HGNC Symbol;Acc:HGNC:7107] -1.26063 
16665083 --- --- -1.25446 
16707196 IFIT1 interferon-induced protein with tetratricopeptide repeats 1 [Source:HGNC 
Symbol;Acc:HGNC:5407] 
-1.25149 
16832429 TMEM97 transmembrane protein 97 [Source:HGNC Symbol;Acc:HGNC:28106] -1.24236 
16799724 DLL4 delta-like 4 (Drosophila) [Source:HGNC Symbol;Acc:HGNC:2910] -1.23867 
16882975 NCAPH non-SMC condensin I complex, subunit H [Source:HGNC Symbol;Acc:HGNC:1112] -1.23766 
16901755 BUB1 BUB1 mitotic checkpoint serine/threonine kinase [Source:HGNC 
Symbol;Acc:HGNC:1148] 
-1.22838 
17080595 DSCC1 DNA replication and sister chromatid cohesion 1 [Source:HGNC 
Symbol;Acc:HGNC:24453] 
-1.21952 
17073259 LY6E lymphocyte antigen 6 complex, locus E [Source:HGNC Symbol;Acc:HGNC:6727] -1.2134 
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16911212 MCM8 minichromosome maintenance complex component 8 [Source:HGNC 
Symbol;Acc:HGNC:16147] 
-1.21168 
16869588 ASF1B anti-silencing function 1B histone chaperone [Source:HGNC 
Symbol;Acc:HGNC:20996] 
-1.20891 
17014358 RP1-249F5.3 Novel transcript -1.20702 
16900441 DUSP2 dual specificity phosphatase 2 [Source:HGNC Symbol;Acc:HGNC:3068] -1.20217 
16777278 SKA3 spindle and kinetochore associated complex subunit 3 [Source:HGNC 
Symbol;Acc:HGNC:20262] 
-1.20129 
16686796 STIL SCL/TAL1 interrupting locus [Source:HGNC Symbol;Acc:HGNC:10879] -1.19581 
16679411 EXO1 exonuclease 1 [Source:HGNC Symbol;Acc:HGNC:3511] -1.1886 
16741501 DHCR7 7-dehydrocholesterol reductase [Source:HGNC Symbol;Acc:HGNC:2860] -1.18506 
16802838 RP11-272D12.1 Novel transcript -1.18468 
16852858 SERPINB7 serpin peptidase inhibitor, clade B (ovalbumin), member 7 [Source:HGNC 
Symbol;Acc:HGNC:13902] 
-1.18131 
16962632 P3H2 prolyl 3-hydroxylase 2 [Source:HGNC Symbol;Acc:HGNC:19317] -1.17795 
17016499 HIST1H1B histone cluster 1, H1b [Source:HGNC Symbol;Acc:HGNC:4719] -1.1738 
16800355 WDR76 WD repeat domain 76 [Source:HGNC Symbol;Acc:HGNC:25773] -1.15908 
16687618 DHCR24 24-dehydrocholesterol reductase [Source:HGNC Symbol;Acc:HGNC:2859] -1.15263 
16799637 RAD51 RAD51 recombinase [Source:HGNC Symbol;Acc:HGNC:9817] -1.15118 
16804559 FANCI Fanconi anemia, complementation group I [Source:HGNC Symbol;Acc:HGNC:25568] -1.15065 
16799793 NUSAP1 nucleolar and spindle associated protein 1 [Source:HGNC Symbol;Acc:HGNC:18538] -1.1438 
17080749 ATAD2 ATPase family, AAA domain containing 2 [Source:HGNC 
Symbol;Acc:HGNC:30123] 
-1.11597 
16903090 MCM6 minichromosome maintenance complex component 6 [Source:HGNC 
Symbol;Acc:HGNC:6949] 
-1.11384 
17067231 PTK2B protein tyrosine kinase 2 beta [Source:HGNC Symbol;Acc:HGNC:9612] -1.10854 
16763926 --- --- -1.09536 
17121990 ZNF730 zinc finger protein 730 [Source:HGNC Symbol;Acc:HGNC:32470] -1.08445 
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16689400 GBP5 guanylate binding protein 5 [Source:HGNC Symbol;Acc:HGNC:19895] -1.08386 
17020019 MCM3 minichromosome maintenance complex component 3 [Source:HGNC 
Symbol;Acc:HGNC:6945] 
-1.07626 
16970563 PLK4 polo-like kinase 4 [Source:HGNC Symbol;Acc:HGNC:11397] -1.07621 
16743686 MMP8 matrix metallopeptidase 8 [Source:HGNC Symbol;Acc:HGNC:7175] -1.06327 
16968735 HERC6 HECT and RLD domain containing E3 ubiquitin protein ligase family member 6 
[Source:HGNC Symbol;Acc:HGNC:26072] 
-1.06251 
17105401 CENPI centromere protein I [Source:HGNC Symbol;Acc:HGNC:3968] -1.05133 
16725742 FADS2 Fatty Acid Desaturase 2[Source:HGNC Symbol;Acc:HGNC:3575] -1.04559 
16743721 MMP1 matrix metallopeptidase 1 [Source:HGNC Symbol;Acc:HGNC:7155] -1.03982 
17057946 PSPH phosphoserine phosphatase [Source:HGNC Symbol;Acc:HGNC:9577] -1.03575 
16996813 CD180 CD180 molecule [Source:HGNC Symbol;Acc:HGNC:6726] -1.03128 
16736638 E2F8 E2F transcription factor 8 [Source:HGNC Symbol;Acc:HGNC:24727] -1.02866 
17014309 ACAT2 acetyl-CoA acetyltransferase 2 [Source:HGNC Symbol;Acc:HGNC:94] -1.02657 
16768923 SLC9A7P1 solute carrier family 9, subfamily A (NHE7, cation proton antiporter 7), member 7 
pseudogene 1 [Source:HGNC Symbol;Acc:HGNC:32679] 
-1.02643 
17068782 MCM4 minichromosome maintenance complex component 4 [Source:HGNC 
Symbol;Acc:HGNC:6947] 
-1.00873 
16897026 ZFP36L2 ZFP36 ring finger protein-like 2 [Source:HGNC Symbol;Acc:HGNC:1108] -0.99468 
16850107 FASN fatty acid synthase [Source:HGNC Symbol;Acc:HGNC:3594] -0.9922 
16913957 MYBL2 v-myb avian myeloblastosis viral oncogene homolog-like 2 [Source:HGNC 
Symbol;Acc:HGNC:7548] 
-0.99002 
16916958 PCNA proliferating cell nuclear antigen [Source:HGNC Symbol;Acc:HGNC:8729] -0.98979 
16995890 HMGCS1 3-hydroxy-3-methylglutaryl-CoA synthase 1 (soluble) [Source:HGNC 
Symbol;Acc:HGNC:5007] 
-0.98191 
16733104 CHEK1 checkpoint kinase 1 [Source:HGNC Symbol;Acc:HGNC:1925] -0.97452 
16900090 --- --- -0.95088 
16723662 FJX1 four jointed box 1 [Source:HGNC Symbol;Acc:HGNC:17166] -0.94352 
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16957951 POLQ polymerase (DNA directed), theta [Source:HGNC Symbol;Acc:HGNC:9186] -0.94286 
16671738 FDPS farnesyl diphosphate synthase [Source:HGNC Symbol;Acc:HGNC:3631] -0.93997 
16758052 P2RX7 purinergic receptor P2X, ligand gated ion channel, 7 [Source:HGNC 
Symbol;Acc:HGNC:8537] 
-0.9363 
16821174 VAT1L vesicle amine transport 1-like [Source:HGNC Symbol;Acc:HGNC:29315] -0.928 
17060412 MCM7 minichromosome maintenance complex component 7 [Source:HGNC 
Symbol;Acc:HGNC:6950] 
-0.92716 
16700699 RP11-443B7.3 uncharacterized  -0.92035 
16978568 CENPE centromere protein E, 312kDa [Source:HGNC Symbol;Acc:HGNC:1856] -0.92017 
16996722 CENPK centromere protein K [Source:HGNC Symbol;Acc:HGNC:29479] -0.91942 
16971737 GUCY1B3 guanylate cyclase 1, soluble, beta 3 [Source:HGNC Symbol;Acc:HGNC:4687] -0.90563 
16792615 C14orf182 Chromosome 14 Open Reading Frame 182 [Source:HGNC 
Symbol;Acc:HGNC:27503] 
-0.90269 
16988703 LMNB1 lamin B1 [Source:HGNC Symbol;Acc:HGNC:6637] -0.90146 
16729557 DDIAS DNA damage-induced apoptosis suppressor [Source:HGNC 
Symbol;Acc:HGNC:26351] 
-0.88615 
16760889 C3AR1 complement component 3a receptor 1 [Source:HGNC Symbol;Acc:HGNC:1319] -0.87944 
16721835 WEE1 WEE1 G2 checkpoint kinase [Source:HGNC Symbol;Acc:HGNC:12761] -0.84931 
16787814 IFI27 interferon, alpha-inducible protein 27 [Source:HGNC Symbol;Acc:HGNC:5397] -0.8247 
16923549 LOC102725378 uncharacterized  -0.82168 
16953279 CDC25A cell division cycle 25A [Source:HGNC Symbol;Acc:HGNC:1725] -0.81485 
16917183 JAG1 jagged 1 [Source:HGNC Symbol;Acc:HGNC:6188] -0.80423 
17030627 LST1 leukocyte specific transcript 1 [Source:HGNC Symbol;Acc:HGNC:14189] -0.7952 
17035425 LST1 leukocyte specific transcript 1 [Source:HGNC Symbol;Acc:HGNC:14189] -0.7952 
17027801 LST1 leukocyte specific transcript 1 [Source:HGNC Symbol;Acc:HGNC:14189] -0.78947 
17033344 LST1 leukocyte specific transcript 1 [Source:HGNC Symbol;Acc:HGNC:14189] -0.78947 
16675794 NAV1 neuron navigator 1 [Source:HGNC Symbol;Acc:HGNC:15989] -0.76481 
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16858386 LDLR low density lipoprotein receptor [Source:HGNC Symbol;Acc:HGNC:6547] -0.75917 
16794966 C14orf1 chromosome 14 open reading frame 1 [Source:HGNC Symbol;Acc:HGNC:1187] -0.75121 
16739132 FADS1 fatty acid desaturase 1 [Source:HGNC Symbol;Acc:HGNC:3574] -0.73089 
17124612 AC003092.1 putative novel transcript -0.7298 
16662648 CDCA8 cell division cycle associated 8 [Source:HGNC Symbol;Acc:HGNC:14629] -0.71305 
17120696 RP11-705C15.2 uncharacterized  -0.70986 
 
THP-1 macrophages were incubated with LPL hydrolysis products or non-hydrolysis products for 18 h. RNA from the treated 
cells were subjected to human gene 2.0ST array (n=3). Using R studio, a top list of up-regulated genes in LPL hydrolysis product 
treated macrophages were obtained at FDR ≤0.03. Log2FC represents 2-fold change of modulated transcript in macrophages 
treated with LPL hydrolysis products compared to control. 
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Figure S4: Enrichment analysis on biological processes modulated by LPL 
hydrolysis products 
GO biological process GO term ID FDR Genes 
in list 
Gene in 
genome 
Cell cycle 
DNA replication* GO:0006260 7×10-7 16 222 
DNA-dependent DNA 
replication 
GO:0006261 7×10-5 10 102 
DNA strand elongation 
involved in DNA replication 
GO:0006271 6×10-4 6 34 
DNA strand elongation GO:0022616 9×10-4 6 37 
MCM complex GO:0042555  7×10-5 5 11 
chromosome segregation GO:0007059 3×10-4 10 128 
sister chromatid segregation GO:0000819 0.006 6 54 
mitotic sister chromatid 
segregation 
GO:0000070 0.024 5 49 
chromosome condensation* GO:0030261 0.012 4 19 
mitotic chromosome 
condensation 
GO:0007076 0.047 3 12 
condensed chromosome GO:0000793 1×10-4 9 86 
chromosome, centromeric 
region 
GO:0000775 0.012 7 98 
condensed chromosome 
kinetochore 
GO:0000777 0.017 4 22 
condensed chromosome 
outer kinetochore 
GO:0000940 0.036 3 11 
DNA packaging GO:0006323 0.008 7 88 
DNA conformation change GO:0071103 0.012 8 135 
nuclear division GO:0000280 0.008 11 257 
organelle fission GO:0048285 0.014 11 282 
G2 DNA damage 
checkpoint 
GO:0031572 0.033 4 28 
protein-DNA complex GO:0032993 0.001 10 158 
G1/S transition of mitotic 
cell cycle 
GO:0000082 0.001 11 201 
Antiviral response 
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cellular response to type I 
interferon 
GO:0071357 4×10-4 8 74 
response to type I 
interferon* 
GO:0034340 4×10-4 8 75 
type I interferon signaling 
pathway 
 GO:0060337 4×10-4 8 74 
response to virus GO:0009615 0.024 9 205 
Stress response 
response to unfolded 
protein* 
 GO:0006986 0.003 8 106 
cellular response to 
unfolded protein 
 GO:0034620 0.024 6 79 
response to topologically 
incorrect protein 
GO:0035966 0.005 8 113 
cellular response to 
topologically incorrect 
protein 
 GO:0035967 0.03 6 84 
activation of signaling 
protein activity involved in 
unfolded protein response 
 GO:0006987 0.012 6 65 
response to endoplasmic 
reticulum stress 
GO:0034976 0.023 7 113 
endoplasmic reticulum 
unfolded protein response 
 GO:0030968 0.024 6 78 
ER-nucleus signaling 
pathway 
 GO:0006984 0.033 6 86 
Ion homeostasis 
cellular metal ion 
homeostasis* 
 GO:0006875 0.01 11 264 
cellular cation homeostasis  GO:0030003 0.015 11 284 
metal ion homeostasis  GO:0055065 0.016 11 288 
cellular ion homeostasis  GO:0006873 0.017 11 292 
Lipid metabolic process 
sterol metabolic process*  GO:0016125 0.024 6 80 
Hydrolase activity 
regulation of nuclease 
activity* 
GO:0032069 7×10-5 9 73 
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positive regulation of 
nuclease activity 
 GO:0032075 0.002 7 67 
Viral life cycle 
regulation of viral genome 
replication 
 GO:0045069 0.028 5 51 
 
Microarray data analysis showed that several genes were differentially regulated by 
lipoprotein hydrolysis products liberated by LPL. To understand the functions of 
modulated genes, enrichment analysis on biological processes was performed using the 
GeneMANIA database (158). My data revealed that several biological processes were 
significantly enriched (with FDR<0.05) following LPL hydrolysis product treatment. Each 
biological process term is derived from a root process (parent term) that possesses sub-
categories (child terms), in addition to their relationship with other GO terms (co-occurring 
terms). The relationship between each and every biological process that was significantly 
over-represented in the list were carefully considered and grouped all child terms and co-
occurring terms under their parent term. The underlined processes are parent terms. *, 
represent child terms that were selected for gene validation  
 
 
 
 
 
 
 
 
 
 
 
 
